Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
Immune checkpoint molecules are promising anticancer targets, among which therapeutic antibodies targeting the PD-1/PD-L1 pathway have been widely applied to cancer treatment in clinical practice and have great potential. However, this treatment is greatly limited by its low response rates in certai...
Saved in:
| Published in | Journal of hematology and oncology Vol. 15; no. 1; pp. 24 - 58 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
12.03.2022
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Immune checkpoint molecules are promising anticancer targets, among which therapeutic antibodies targeting the PD-1/PD-L1 pathway have been widely applied to cancer treatment in clinical practice and have great potential. However, this treatment is greatly limited by its low response rates in certain cancers, lack of known biomarkers, immune-related toxicity, innate and acquired drug resistance, etc. Overcoming these limitations would significantly expand the anticancer applications of PD-1/PD-L1 blockade and improve the response rate and survival time of cancer patients. In the present review, we first illustrate the biological mechanisms of the PD-1/PD-L1 immune checkpoints and their role in the healthy immune system as well as in the tumor microenvironment (TME). The PD-1/PD-L1 pathway inhibits the anticancer effect of T cells in the TME, which in turn regulates the expression levels of PD-1 and PD-L1 through multiple mechanisms. Several strategies have been proposed to solve the limitations of anti-PD-1/PD-L1 treatment, including combination therapy with other standard treatments, such as chemotherapy, radiotherapy, targeted therapy, anti-angiogenic therapy, other immunotherapies and even diet control. Downregulation of PD-L1 expression in the TME via pharmacological or gene regulation methods improves the efficacy of anti-PD-1/PD-L1 treatment. Surprisingly, recent preclinical studies have shown that upregulation of PD-L1 in the TME also improves the response and efficacy of immune checkpoint blockade. Immunotherapy is a promising anticancer strategy that provides novel insight into clinical applications. This review aims to guide the development of more effective and less toxic anti-PD-1/PD-L1 immunotherapies. |
|---|---|
| AbstractList | Immune checkpoint molecules are promising anticancer targets, among which therapeutic antibodies targeting the PD-1/PD-L1 pathway have been widely applied to cancer treatment in clinical practice and have great potential. However, this treatment is greatly limited by its low response rates in certain cancers, lack of known biomarkers, immune-related toxicity, innate and acquired drug resistance, etc. Overcoming these limitations would significantly expand the anticancer applications of PD-1/PD-L1 blockade and improve the response rate and survival time of cancer patients. In the present review, we first illustrate the biological mechanisms of the PD-1/PD-L1 immune checkpoints and their role in the healthy immune system as well as in the tumor microenvironment (TME). The PD-1/PD-L1 pathway inhibits the anticancer effect of T cells in the TME, which in turn regulates the expression levels of PD-1 and PD-L1 through multiple mechanisms. Several strategies have been proposed to solve the limitations of anti-PD-1/PD-L1 treatment, including combination therapy with other standard treatments, such as chemotherapy, radiotherapy, targeted therapy, anti-angiogenic therapy, other immunotherapies and even diet control. Downregulation of PD-L1 expression in the TME via pharmacological or gene regulation methods improves the efficacy of anti-PD-1/PD-L1 treatment. Surprisingly, recent preclinical studies have shown that upregulation of PD-L1 in the TME also improves the response and efficacy of immune checkpoint blockade. Immunotherapy is a promising anticancer strategy that provides novel insight into clinical applications. This review aims to guide the development of more effective and less toxic anti-PD-1/PD-L1 immunotherapies. Immune checkpoint molecules are promising anticancer targets, among which therapeutic antibodies targeting the PD-1/PD-L1 pathway have been widely applied to cancer treatment in clinical practice and have great potential. However, this treatment is greatly limited by its low response rates in certain cancers, lack of known biomarkers, immune-related toxicity, innate and acquired drug resistance, etc. Overcoming these limitations would significantly expand the anticancer applications of PD-1/PD-L1 blockade and improve the response rate and survival time of cancer patients. In the present review, we first illustrate the biological mechanisms of the PD-1/PD-L1 immune checkpoints and their role in the healthy immune system as well as in the tumor microenvironment (TME). The PD-1/PD-L1 pathway inhibits the anticancer effect of T cells in the TME, which in turn regulates the expression levels of PD-1 and PD-L1 through multiple mechanisms. Several strategies have been proposed to solve the limitations of anti-PD-1/PD-L1 treatment, including combination therapy with other standard treatments, such as chemotherapy, radiotherapy, targeted therapy, anti-angiogenic therapy, other immunotherapies and even diet control. Downregulation of PD-L1 expression in the TME via pharmacological or gene regulation methods improves the efficacy of anti-PD-1/PD-L1 treatment. Surprisingly, recent preclinical studies have shown that upregulation of PD-L1 in the TME also improves the response and efficacy of immune checkpoint blockade. Immunotherapy is a promising anticancer strategy that provides novel insight into clinical applications. This review aims to guide the development of more effective and less toxic anti-PD-1/PD-L1 immunotherapies. Keywords: Immunotherapy, PD-1/PD-L1, Combination therapy, PD-L1 regulation Immune checkpoint molecules are promising anticancer targets, among which therapeutic antibodies targeting the PD-1/PD-L1 pathway have been widely applied to cancer treatment in clinical practice and have great potential. However, this treatment is greatly limited by its low response rates in certain cancers, lack of known biomarkers, immune-related toxicity, innate and acquired drug resistance, etc. Overcoming these limitations would significantly expand the anticancer applications of PD-1/PD-L1 blockade and improve the response rate and survival time of cancer patients. In the present review, we first illustrate the biological mechanisms of the PD-1/PD-L1 immune checkpoints and their role in the healthy immune system as well as in the tumor microenvironment (TME). The PD-1/PD-L1 pathway inhibits the anticancer effect of T cells in the TME, which in turn regulates the expression levels of PD-1 and PD-L1 through multiple mechanisms. Several strategies have been proposed to solve the limitations of anti-PD-1/PD-L1 treatment, including combination therapy with other standard treatments, such as chemotherapy, radiotherapy, targeted therapy, anti-angiogenic therapy, other immunotherapies and even diet control. Downregulation of PD-L1 expression in the TME via pharmacological or gene regulation methods improves the efficacy of anti-PD-1/PD-L1 treatment. Surprisingly, recent preclinical studies have shown that upregulation of PD-L1 in the TME also improves the response and efficacy of immune checkpoint blockade. Immunotherapy is a promising anticancer strategy that provides novel insight into clinical applications. This review aims to guide the development of more effective and less toxic anti-PD-1/PD-L1 immunotherapies.Immune checkpoint molecules are promising anticancer targets, among which therapeutic antibodies targeting the PD-1/PD-L1 pathway have been widely applied to cancer treatment in clinical practice and have great potential. However, this treatment is greatly limited by its low response rates in certain cancers, lack of known biomarkers, immune-related toxicity, innate and acquired drug resistance, etc. Overcoming these limitations would significantly expand the anticancer applications of PD-1/PD-L1 blockade and improve the response rate and survival time of cancer patients. In the present review, we first illustrate the biological mechanisms of the PD-1/PD-L1 immune checkpoints and their role in the healthy immune system as well as in the tumor microenvironment (TME). The PD-1/PD-L1 pathway inhibits the anticancer effect of T cells in the TME, which in turn regulates the expression levels of PD-1 and PD-L1 through multiple mechanisms. Several strategies have been proposed to solve the limitations of anti-PD-1/PD-L1 treatment, including combination therapy with other standard treatments, such as chemotherapy, radiotherapy, targeted therapy, anti-angiogenic therapy, other immunotherapies and even diet control. Downregulation of PD-L1 expression in the TME via pharmacological or gene regulation methods improves the efficacy of anti-PD-1/PD-L1 treatment. Surprisingly, recent preclinical studies have shown that upregulation of PD-L1 in the TME also improves the response and efficacy of immune checkpoint blockade. Immunotherapy is a promising anticancer strategy that provides novel insight into clinical applications. This review aims to guide the development of more effective and less toxic anti-PD-1/PD-L1 immunotherapies. Abstract Immune checkpoint molecules are promising anticancer targets, among which therapeutic antibodies targeting the PD-1/PD-L1 pathway have been widely applied to cancer treatment in clinical practice and have great potential. However, this treatment is greatly limited by its low response rates in certain cancers, lack of known biomarkers, immune-related toxicity, innate and acquired drug resistance, etc. Overcoming these limitations would significantly expand the anticancer applications of PD-1/PD-L1 blockade and improve the response rate and survival time of cancer patients. In the present review, we first illustrate the biological mechanisms of the PD-1/PD-L1 immune checkpoints and their role in the healthy immune system as well as in the tumor microenvironment (TME). The PD-1/PD-L1 pathway inhibits the anticancer effect of T cells in the TME, which in turn regulates the expression levels of PD-1 and PD-L1 through multiple mechanisms. Several strategies have been proposed to solve the limitations of anti-PD-1/PD-L1 treatment, including combination therapy with other standard treatments, such as chemotherapy, radiotherapy, targeted therapy, anti-angiogenic therapy, other immunotherapies and even diet control. Downregulation of PD-L1 expression in the TME via pharmacological or gene regulation methods improves the efficacy of anti-PD-1/PD-L1 treatment. Surprisingly, recent preclinical studies have shown that upregulation of PD-L1 in the TME also improves the response and efficacy of immune checkpoint blockade. Immunotherapy is a promising anticancer strategy that provides novel insight into clinical applications. This review aims to guide the development of more effective and less toxic anti-PD-1/PD-L1 immunotherapies. |
| ArticleNumber | 24 |
| Audience | Academic |
| Author | Xia, Yong Xie, Yao Zhang, Yiwen Ma, Hongbo Wu, Mengling Huang, Qianrui Wu, Xuyi |
| Author_xml | – sequence: 1 givenname: Mengling surname: Wu fullname: Wu, Mengling – sequence: 2 givenname: Qianrui surname: Huang fullname: Huang, Qianrui – sequence: 3 givenname: Yao surname: Xie fullname: Xie, Yao – sequence: 4 givenname: Xuyi surname: Wu fullname: Wu, Xuyi – sequence: 5 givenname: Hongbo surname: Ma fullname: Ma, Hongbo – sequence: 6 givenname: Yiwen surname: Zhang fullname: Zhang, Yiwen – sequence: 7 givenname: Yong surname: Xia fullname: Xia, Yong |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35279217$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kl2LEzEUhgdZcT_0D3ghA8Lizezma_JxIyyr7hYKeqHX4UwmaVNnJjWZFvrvTTvr0opIIAk5z_uSk7yXxdkQBlsUbzG6wVjy24QpYnWFCKkQJoxU5EVxgUXNKykIOTvanxeXKa0Q4lgR9Ko4pzURimBxUaxm_TqGre3tMJbBlePSljCM3sBgbCytc3lrdvvSt08Vvs3THJdNF8xPaG259VCa0Dd-gNGHYS-PsN5li7ac0GgXm-5QfF28dNAl--ZpvSp-fPn8_f6xmn99mN3fzSvDKRkr6kSNDK1pgwATVAug2JHWCWIUVo1gkhPaOCCCGgFEYgHIMi5Uy0VLSUuvitnk2wZY6XX0PcSdDuD14SDEhYaYO-ysZtJiJ8E5jhnL9tAwJBGXDAklkILs9XHyWm-a3rYmv1KE7sT0tDL4pV6ErZYKC4FoNvjwZBDDr41No-59MrbrYLBhkzThVCqOGKsz-n5CF5Cv5gcXsqPZ4_qOK1WTjOFM3fyDyqO1vTc5IM7n8xPB9ZFgaaEblyl0m_2XpFPw3XGvz03-CUsGyASYGFKK1j0jGOl9IvWUSJ0TqQ-J1CSL5F8i48dDHvK9ffc_6W8tVeCx |
| CitedBy_id | crossref_primary_10_1016_j_molimm_2024_08_006 crossref_primary_10_1016_j_canlet_2022_216009 crossref_primary_10_4062_biomolther_2022_153 crossref_primary_10_1016_j_phymed_2024_155497 crossref_primary_10_3389_fimmu_2023_1237964 crossref_primary_10_1016_j_heliyon_2024_e37958 crossref_primary_10_1016_j_ctro_2024_100906 crossref_primary_10_1007_s12272_024_01516_y crossref_primary_10_1016_j_nantod_2023_102076 crossref_primary_10_1016_j_apsb_2024_01_017 crossref_primary_10_1007_s10238_024_01482_1 crossref_primary_10_1124_jpet_123_001898 crossref_primary_10_1016_j_apsb_2025_03_026 crossref_primary_10_3390_cancers14143368 crossref_primary_10_36401_JIPO_23_16 crossref_primary_10_1016_j_prp_2025_155864 crossref_primary_10_1186_s12943_023_01900_0 crossref_primary_10_3390_biomedicines12010217 crossref_primary_10_3390_antiox13030380 crossref_primary_10_1016_j_ejmech_2023_115599 crossref_primary_10_1016_j_bioactmat_2024_05_014 crossref_primary_10_1186_s12964_023_01348_1 crossref_primary_10_1016_j_intimp_2024_112621 crossref_primary_10_1186_s40164_024_00506_6 crossref_primary_10_3389_fimmu_2024_1494138 crossref_primary_10_3390_cells12202439 crossref_primary_10_1007_s10143_025_03418_z crossref_primary_10_2147_IJN_S504363 crossref_primary_10_1002_advs_202400340 crossref_primary_10_3390_molecules28237881 crossref_primary_10_1186_s13045_023_01405_9 crossref_primary_10_1007_s12672_023_00766_4 crossref_primary_10_1016_j_bbcan_2025_189284 crossref_primary_10_3390_cancers17020226 crossref_primary_10_1038_s41598_025_93486_4 crossref_primary_10_1155_2024_8481761 crossref_primary_10_1016_j_jconrel_2022_12_037 crossref_primary_10_1016_j_biomaterials_2025_123094 crossref_primary_10_3390_onco4030010 crossref_primary_10_1038_s41598_025_87687_0 crossref_primary_10_1186_s12951_023_02240_3 crossref_primary_10_1016_j_jare_2024_12_043 crossref_primary_10_4049_jimmunol_2200389 crossref_primary_10_1021_acsnano_4c03034 crossref_primary_10_1016_j_jtho_2022_11_015 crossref_primary_10_1016_j_talanta_2024_127258 crossref_primary_10_1016_j_isci_2025_111819 crossref_primary_10_1016_j_canlet_2024_216969 crossref_primary_10_1016_j_nantod_2024_102286 crossref_primary_10_1155_2023_7692726 crossref_primary_10_2147_IJN_S469217 crossref_primary_10_1093_oncolo_oyae102 crossref_primary_10_1111_bph_17404 crossref_primary_10_1096_fj_202302288R crossref_primary_10_1007_s00432_024_05869_1 crossref_primary_10_1021_acs_molpharmaceut_4c00137 crossref_primary_10_1038_s41420_024_02102_3 crossref_primary_10_1016_j_hbpd_2022_08_015 crossref_primary_10_1186_s12943_024_01997_x crossref_primary_10_1136_jitc_2023_007529 crossref_primary_10_1002_adma_202403296 crossref_primary_10_1038_s41392_024_01759_7 crossref_primary_10_1016_j_jpha_2023_04_009 crossref_primary_10_1007_s00259_023_06485_w crossref_primary_10_3389_fonc_2023_1210297 crossref_primary_10_1186_s13045_025_01678_2 crossref_primary_10_1126_sciadv_ade5393 crossref_primary_10_3389_fonc_2024_1371752 crossref_primary_10_1016_j_critrevonc_2024_104403 crossref_primary_10_1186_s13020_023_00785_x crossref_primary_10_21320_2500_2139_2023_16_3_268_279 crossref_primary_10_3892_ijo_2025_5734 crossref_primary_10_1016_j_oor_2024_100490 crossref_primary_10_2147_JIR_S509316 crossref_primary_10_3389_fimmu_2022_937307 crossref_primary_10_3389_fimmu_2023_1269341 crossref_primary_10_3389_fimmu_2022_1012499 crossref_primary_10_1016_j_ipha_2024_07_006 crossref_primary_10_1186_s13045_022_01328_x crossref_primary_10_1016_j_intimp_2024_111698 crossref_primary_10_1080_2162402X_2023_2219544 crossref_primary_10_1016_j_canlet_2022_215814 crossref_primary_10_1016_j_ejca_2024_115069 crossref_primary_10_1016_j_critrevonc_2023_103920 crossref_primary_10_1186_s40364_023_00543_z crossref_primary_10_1186_s13048_023_01260_9 crossref_primary_10_1097_JS9_0000000000001082 crossref_primary_10_1097_CM9_0000000000002426 crossref_primary_10_3389_fimmu_2022_927635 crossref_primary_10_3389_fbioe_2022_1066869 crossref_primary_10_1016_j_biomaterials_2023_122392 crossref_primary_10_18632_aging_205689 crossref_primary_10_3390_cancers15174265 crossref_primary_10_1186_s12964_024_01633_7 crossref_primary_10_1002_advs_202410632 crossref_primary_10_1007_s00428_025_04039_z crossref_primary_10_3390_cimb46010009 crossref_primary_10_1016_j_ejmech_2023_115684 crossref_primary_10_1186_s12943_024_02099_4 crossref_primary_10_1016_j_ymthe_2024_07_014 crossref_primary_10_5230_jgc_2022_22_e35 crossref_primary_10_1016_j_intimp_2023_111147 crossref_primary_10_3389_fimmu_2023_1127623 crossref_primary_10_3389_fimmu_2025_1548452 crossref_primary_10_3390_ijms232112892 crossref_primary_10_3390_pharmaceutics16091228 crossref_primary_10_2147_IJN_S461289 crossref_primary_10_1002_adfm_202416563 crossref_primary_10_3389_fonc_2024_1445358 crossref_primary_10_1002_cac2_12579 crossref_primary_10_3389_fimmu_2023_1309055 crossref_primary_10_1007_s12094_024_03491_8 crossref_primary_10_1002_cac2_12576 crossref_primary_10_1016_j_intimp_2024_112098 crossref_primary_10_3389_fonc_2023_1146905 crossref_primary_10_1016_j_canlet_2024_217350 crossref_primary_10_1073_pnas_2408354121 crossref_primary_10_1016_j_heliyon_2024_e38710 crossref_primary_10_1039_D3BM01118F crossref_primary_10_2147_JIR_S377678 crossref_primary_10_1186_s40001_023_01486_9 crossref_primary_10_3390_cancers16162919 crossref_primary_10_3390_cells13171444 crossref_primary_10_1007_s13402_022_00716_2 crossref_primary_10_3390_pharmaceutics14122612 crossref_primary_10_1016_j_cclet_2024_110317 crossref_primary_10_1093_jleuko_qiae151 crossref_primary_10_3389_fphar_2023_1132158 crossref_primary_10_1016_j_cej_2024_152129 crossref_primary_10_1002_advs_202307870 crossref_primary_10_1002_advs_202413122 crossref_primary_10_3390_biomedicines10061441 crossref_primary_10_1186_s40164_024_00587_3 crossref_primary_10_1007_s00432_023_05552_x crossref_primary_10_1126_sciadv_adh9069 crossref_primary_10_1186_s40164_024_00539_x crossref_primary_10_1155_2022_4033863 crossref_primary_10_3390_cancers16020309 crossref_primary_10_1007_s00262_022_03308_z crossref_primary_10_3389_fphar_2023_1261575 crossref_primary_10_1016_j_biopha_2022_113618 crossref_primary_10_1016_j_bspc_2023_104815 crossref_primary_10_1021_acs_jmedchem_2c01719 crossref_primary_10_1186_s40164_024_00591_7 crossref_primary_10_1038_s41419_022_05375_7 crossref_primary_10_1097_HC9_0000000000000633 crossref_primary_10_3389_fonc_2024_1441222 crossref_primary_10_1016_j_bcp_2024_116162 crossref_primary_10_1039_D3TB01358H crossref_primary_10_3724_zdxbyxb_2023_0263 crossref_primary_10_1016_j_ijbiomac_2025_139537 crossref_primary_10_1038_s41417_023_00713_z crossref_primary_10_20517_evcna_2023_75 crossref_primary_10_5306_wjco_v15_i9_1136 crossref_primary_10_1111_imm_13755 crossref_primary_10_1016_j_apsb_2023_12_004 crossref_primary_10_2147_OTT_S410693 crossref_primary_10_1021_acsbiomaterials_2c00639 crossref_primary_10_1002_adhm_202401538 crossref_primary_10_1016_j_apsb_2023_08_014 crossref_primary_10_1016_j_cytogfr_2024_02_003 crossref_primary_10_3389_fimmu_2024_1472772 crossref_primary_10_1016_j_cej_2023_145516 crossref_primary_10_1186_s40364_022_00381_5 crossref_primary_10_1002_cai2_70003 crossref_primary_10_1021_acsnano_3c01019 crossref_primary_10_1002_ctm2_1543 crossref_primary_10_1016_j_trecan_2023_06_002 crossref_primary_10_3389_fimmu_2023_1274547 crossref_primary_10_1002_adhm_202304284 crossref_primary_10_1021_acsnano_4c08448 crossref_primary_10_3389_fmed_2024_1515263 crossref_primary_10_3389_fphar_2022_987569 crossref_primary_10_2340_1651_226X_2024_19462 crossref_primary_10_1002_adhm_202300110 crossref_primary_10_3389_fimmu_2024_1412328 crossref_primary_10_1021_acs_jmedchem_4c00102 crossref_primary_10_1016_j_canlet_2024_217152 crossref_primary_10_3390_ijms24031894 crossref_primary_10_1016_j_fbio_2025_106005 crossref_primary_10_3390_cancers15235495 crossref_primary_10_1038_s41416_022_02128_3 crossref_primary_10_1136_jitc_2024_010521 crossref_primary_10_3390_md21020132 crossref_primary_10_1016_j_bbcan_2022_188761 crossref_primary_10_1186_s13045_023_01436_2 crossref_primary_10_1080_2162402X_2024_2371575 crossref_primary_10_1186_s40164_022_00297_8 crossref_primary_10_1186_s40644_025_00849_1 crossref_primary_10_3390_biom14091191 crossref_primary_10_1007_s12672_023_00758_4 crossref_primary_10_1186_s13045_022_01307_2 crossref_primary_10_5306_wjco_v16_i3_100361 crossref_primary_10_1007_s00261_024_04200_3 crossref_primary_10_1186_s40164_023_00446_7 crossref_primary_10_1080_15384047_2023_2278229 crossref_primary_10_1093_toxsci_kfae003 crossref_primary_10_1016_S1875_5364_23_60451_0 crossref_primary_10_2147_IJN_S454004 crossref_primary_10_1016_j_intimp_2024_113809 crossref_primary_10_2147_IJN_S445879 crossref_primary_10_1016_j_apsb_2022_12_021 crossref_primary_10_1186_s13045_024_01524_x crossref_primary_10_1186_s13072_023_00519_1 crossref_primary_10_1186_s12964_023_01354_3 crossref_primary_10_1016_j_intimp_2024_113365 crossref_primary_10_1007_s00262_023_03563_8 crossref_primary_10_1016_j_phymed_2023_155189 crossref_primary_10_1021_acs_molpharmaceut_4c01293 crossref_primary_10_1093_rb_rbae019 crossref_primary_10_1159_000526906 crossref_primary_10_3390_ph16101362 crossref_primary_10_1016_j_colsurfb_2024_114125 crossref_primary_10_1016_j_biomaterials_2022_121700 crossref_primary_10_34057_PPj_2024_43_03_2024_3_2 crossref_primary_10_1016_j_critrevonc_2025_104658 crossref_primary_10_1007_s10238_023_01146_6 crossref_primary_10_1093_bib_bbad457 crossref_primary_10_1080_14756366_2025_2461190 crossref_primary_10_1186_s13045_024_01644_4 crossref_primary_10_1021_acs_bioconjchem_4c00242 crossref_primary_10_1186_s13045_023_01452_2 crossref_primary_10_3389_fimmu_2022_900119 crossref_primary_10_3390_cells13040351 crossref_primary_10_1021_acsnano_3c08939 crossref_primary_10_3390_ijms241310684 crossref_primary_10_1158_2767_9764_CRC_23_0309 crossref_primary_10_1007_s00432_024_05791_6 crossref_primary_10_1016_j_ejphar_2024_176831 crossref_primary_10_3389_fonc_2023_1333761 crossref_primary_10_1016_j_gene_2023_148111 crossref_primary_10_1186_s12943_024_02095_8 crossref_primary_10_1016_j_cej_2024_150908 crossref_primary_10_1016_j_cpt_2025_02_007 crossref_primary_10_1007_s40820_025_01666_8 crossref_primary_10_3390_ncrna9060070 crossref_primary_10_3389_fphar_2022_963054 crossref_primary_10_1016_j_biomaterials_2024_122740 crossref_primary_10_1016_j_intimp_2024_111601 crossref_primary_10_1080_0284186X_2023_2226330 crossref_primary_10_3389_fimmu_2022_925985 crossref_primary_10_1136_jitc_2024_009627 crossref_primary_10_1038_s41392_024_01853_w crossref_primary_10_1136_jitc_2024_009983 crossref_primary_10_1038_s41598_025_91137_2 crossref_primary_10_1186_s13046_023_02753_7 |
| Cites_doi | 10.1016/j.ccell.2021.07.023 10.1016/j.cell.2021.07.020 10.1016/S1470-2045(21)00650-1 10.1158/1078-0432.CCR-17-2664 10.1128/MCB.00319-13 10.1038/labinvest.2013.130 10.1371/journal.pone.0065821 10.18632/oncotarget.23552 10.1158/0008-5472.CAN-20-0471 10.1016/j.cell.2016.03.031 10.3390/cancers12123575 10.1093/annonc/mdy041 10.1136/jitc-2019-000475 10.1016/j.cell.2016.08.069 10.1093/annonc/mdy162 10.1126/sciimmunol.aah5509 10.1038/s41392-021-00795-x 10.1523/JNEUROSCI.5812-12.2013 10.1016/j.redox.2020.101780 10.1016/j.cell.2018.11.021 10.1158/0008-5472.CAN-18-1003 10.1126/science.abl5376 10.1126/scitranslmed.abd1616 10.1016/j.ymthe.2018.11.010 10.1002/adfm.202004940 10.1038/s41571-021-00496-y 10.1016/S1470-2045(21)00333-8 10.1155/2017/1293201 10.1182/blood-2006-11-060087 10.18632/oncotarget.19193 10.1016/j.actbio.2019.08.046 10.1016/j.cllc.2012.05.006 10.1016/j.it.2020.08.010 10.1038/mt.2016.63 10.4049/jimmunol.1601464 10.1038/s41423-018-0021-3 10.1038/nri.2016.107 10.1038/s41467-021-27833-0 10.1080/1744666X.2017.1366315 10.1001/jamaoncol.2021.2301 10.1016/j.ijrobp.2017.06.2051 10.1002/adma.202103497 10.1038/cmi.2014.104 10.1158/1078-0432.CCR-11-0116 10.1186/s12931-019-1137-4 10.1016/j.biomaterials.2020.120579 10.1016/j.ceb.2015.04.013 10.3389/fimmu.2019.02298 10.1126/scitranslmed.3006504 10.1038/bjc.2017.385 10.1038/s41591-021-01673-3 10.1016/j.biochi.2018.06.016 10.1158/0008-5472.CAN-05-4303 10.1093/intimm/dxh194 10.1158/0008-5472.CAN-17-3297 10.1016/j.jtho.2020.11.025 10.1038/s41423-018-0176-y 10.1182/blood-2007-11-123141 10.3390/molecules24061190 10.1002/advs.202001596 10.1111/cas.13072 10.1038/70932 10.7150/jca.26461 10.1016/j.immuni.2013.07.012 10.1073/pnas.1604268113 10.1158/0008-5472.CAN-09-3690 10.1186/s13046-020-1536-x 10.1093/annonc/mdx683 10.1097/JTO.0000000000000500 10.1186/s13045-017-0541-9 10.1016/j.molcel.2018.07.030 10.1016/j.ccell.2021.11.002 10.1016/j.ccell.2021.09.010 10.1186/s12967-015-0678-7 10.1016/j.immuni.2016.07.008 10.1182/blood-2009-02-203141 10.3390/cancers13071639 10.1038/s41586-021-03965-7 10.1016/j.canlet.2019.10.027 10.1158/1078-0432.CCR-12-2731 10.1007/s10549-013-2581-3 10.1016/j.immuni.2016.06.001 10.1038/nrclinonc.2017.88 10.1016/j.cell.2021.09.019 10.1126/scitranslmed.aaz5387 10.1111/cas.14844 10.1016/j.molimm.2011.06.436 10.1016/S1470-2045(16)30498-3 10.1126/science.1129139 10.1056/NEJMoa1200690 10.1016/j.cell.2016.04.009 10.1080/15384101.2018.1489177 10.1136/jitc-2021-003213 10.1016/j.cell.2015.08.052 10.1002/med.21727 10.1126/science.abc1048 10.1001/jamaoncol.2019.1478 10.1186/s13578-020-00499-9 10.2217/imt-2018-0193 10.1073/pnas.1908158117 10.1038/s43018-021-00269-7 10.1158/1078-0432.CCR-16-0224 10.1016/j.lfs.2021.119359 10.1038/ni1443 10.1016/1074-7613(95)90125-6 10.1080/2162402X.2015.1026530 10.1158/1078-0432.CCR-18-1932 10.1126/science.1251102 10.7150/thno.45391 10.1038/nrc.2017.75 10.1056/NEJMoa1200694 10.1002/eji.200526347 10.1016/j.cell.2018.08.027 10.1006/geno.1994.1562 10.1016/j.det.2015.05.008 10.1200/JCO.21.01862 10.1155/2011/451694 10.1084/jem.192.7.1027 10.1038/nm.2106 10.1038/s41467-020-19192-z 10.1016/j.ctrv.2019.04.003 10.1126/scitranslmed.aag2942 10.1016/j.eururo.2014.12.052 10.1126/sciadv.aay4458 10.1056/NEJMoa1801005 10.1016/j.ccell.2020.08.004 10.1080/2162402X.2017.1412909 10.1371/journal.pone.0088557 10.1038/nature21676 10.1016/j.biopha.2020.110588 10.1083/jcb.201610056 10.1038/s41598-018-38068-3 10.1016/j.canlet.2021.06.007 10.1016/S1470-2045(15)70103-8 10.1073/pnas.0830997100 10.1200/JCO.21.02067 10.1136/jitc-2021-002528 10.1021/acsami.9b07556 10.6004/jnccn.2018.0047 10.1007/s00262-021-03130-z 10.1158/2159-8290.CD-RW2018-017 10.1038/nature24649 10.1158/0008-5472.CAN-16-1577 10.3390/molecules23082071 10.1186/s40425-018-0329-7 10.1136/jitc-2021-002843 10.7554/eLife.52330 10.1038/s41467-021-27303-7 10.1016/j.semcancer.2020.06.009 10.3390/cancers12123816 10.1016/j.ccell.2021.08.008 10.1126/sciimmunol.aar3451 10.1074/jbc.AC119.011747 10.1007/978-1-4939-8600-2_16 10.1084/jem.193.7.839 10.1056/NEJMoa1716078 10.1136/jitc-2019-000416 10.1002/advs.202003404 10.1038/nature21349 10.1158/1078-0432.CCR-16-1761 10.2217/fon-2018-0639 10.1126/science.aad0779 10.1038/nature23449 10.3389/fonc.2019.00264 10.1073/pnas.0509182102 10.1016/j.lungcan.2014.04.001 10.1038/85330 10.1016/j.molcel.2021.03.037 10.1080/2162402X.2021.1943180 10.1136/jitc-2020-001498 10.1080/2162402X.2020.1831153 10.1016/S1470-2045(20)30701-4 10.1016/S0140-6736(21)02098-5 10.1016/j.celrep.2017.04.031 10.1038/s41568-021-00386-6 10.1038/nn.4571 10.2147/OTT.S221340 10.1158/2159-8290.CD-18-0367 10.1038/s41573-018-0007-y 10.1016/j.annonc.2021.05.801 10.1016/j.ccell.2016.10.010 10.1007/s00262-014-1519-x 10.1038/s41591-020-01224-2 10.1016/j.cell.2015.08.015 10.3390/cancers12010057 10.1093/annonc/mdv623 10.1002/j.1460-2075.1992.tb05481.x 10.1111/j.1600-065X.2007.00573.x 10.1177/2050313X20907033 10.4049/jimmunol.1800717 10.1038/nbt.4195 10.1038/onc.2017.217 10.1126/scitranslmed.aay8707 10.1016/S1470-2045(20)30453-8 10.1158/1078-0432.CCR-21-0810 10.1371/journal.ppat.1007468 10.1016/j.cyto.2019.154984 10.1073/pnas.1519623112 10.1084/jem.20180870 10.4049/jimmunol.173.2.945 10.1038/s41416-018-0352-y 10.1016/j.bbcan.2018.12.002 10.1016/j.cell.2009.05.046 10.3390/md17070421 10.1038/nature04444 10.1158/2159-8290.CD-19-0761 10.3390/cells8121602 10.1186/s13046-019-1257-1 10.1186/s12943-018-0928-4 10.1084/jem.20090847 10.1038/s41591-021-01544-x 10.1016/j.jtho.2019.01.016 10.1038/s43018-020-0056-0 10.1073/pnas.0601347103 10.1158/2159-8290.CD-17-0593 10.1371/journal.pone.0251731 10.1158/0008-5472.CAN-20-1674 10.1158/2159-8290.CD-14-0863 10.1111/1440-1681.13056 10.3390/cancers13071725 10.1084/jem.20022089 10.1016/S1470-2045(21)00546-5 10.1038/s41586-021-04161-3 10.1158/0008-5472.CAN-21-0468 10.3389/fimmu.2016.00550 10.7150/jca.57334 10.4049/jimmunol.1003208 10.1016/j.ctrv.2015.09.006 10.1016/j.celrep.2020.108620 10.1186/s12943-015-0421-2 10.1172/JCI141614 10.1126/science.270.5238.985 10.1038/s41591-018-0040-8 10.1126/science.aba1786 10.1038/s43018-021-00245-1 10.1016/S1470-2045(21)00545-3 10.1056/NEJMra1703481 10.1016/j.ctrv.2016.02.003 10.1016/j.tips.2015.06.005 10.1056/NEJMoa2111380 10.1056/NEJMoa1609279 10.1111/cas.14529 10.1016/j.jmgm.2015.01.015 10.1016/j.cell.2012.03.003 10.1002/anie.202011273 10.1038/nrd4663 10.1038/s41586-018-0392-8 10.7150/jca.17648 10.1038/s41467-017-02424-0 10.3892/ijo.2016.3632 10.1038/s41586-020-2502-7 10.1074/jbc.M117.809053 10.1038/ncb1596 10.1038/s41591-021-01462-y 10.1016/j.ccell.2018.01.009 10.1016/j.immuni.2018.03.007 10.1111/apha.12430 10.1016/j.jtho.2017.04.014 10.1034/j.1600-065X.2003.00008.x 10.1158/2159-8290.CD-13-0310 10.4049/jimmunol.170.7.3637 10.3389/fonc.2021.641980 10.1186/s40364-020-00237-w 10.1084/jem.20100643 10.1158/2159-8290.CD-18-1020 10.1126/science.aac9935 10.1186/s40425-018-0454-3 10.1038/s41551-021-00826-6 10.1007/s00262-017-2086-8 10.1186/s12951-018-0428-0 10.1038/s41586-019-1032-7 10.1056/NEJMoa1809615 10.1038/cr.2016.50 10.1002/cam4.4114 10.3390/molecules24112071 10.1016/j.ccell.2020.03.017 10.1038/ni.2035 10.1111/j.1600-065X.2010.00923.x 10.4049/jimmunol.1801199 10.1016/j.jtho.2020.06.015 10.1002/pros.21020 10.1016/j.imlet.2017.02.006 10.1158/2326-6066.CIR-16-0329 10.1158/2326-6066.CIR-16-0365 10.1111/resp.12789 10.1158/0008-5472.CAN-14-3362 10.1016/j.vaccine.2016.04.032 10.1371/journal.pone.0166626 10.1038/s41388-021-01897-0 10.1146/annurev.immunol.26.021607.090331 10.1038/s41467-021-24767-5 10.1016/j.str.2017.06.011 10.1016/j.ccell.2015.10.012 10.1038/s41571-019-0218-0 10.2147/OTT.S247050 10.1080/2162402X.2015.1058597 10.1172/jci.insight.120626 10.3389/fimmu.2020.00487 10.1016/j.bbagrm.2008.08.003 10.3390/jcm10102191 10.1186/s12943-018-0869-y 10.1200/JCO.2014.58.9093 10.1111/j.1600-6143.2012.04224.x 10.1016/S0140-6736(16)00587-0 10.1080/2162402X.2020.1832760 10.1002/1878-0261.12135 10.1001/jama.2017.14155 10.1111/cei.12949 10.3390/cancers13246158 |
| ContentType | Journal Article |
| Copyright | 2022. The Author(s). COPYRIGHT 2022 BioMed Central Ltd. The Author(s) 2022 |
| Copyright_xml | – notice: 2022. The Author(s). – notice: COPYRIGHT 2022 BioMed Central Ltd. – notice: The Author(s) 2022 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1186/s13045-022-01242-2 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1756-8722 |
| EndPage | 58 |
| ExternalDocumentID | oai_doaj_org_article_48e1f8aff6144c91ab4080684079709a PMC8917703 A699526041 35279217 10_1186_s13045_022_01242_2 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Review |
| GrantInformation_xml | – fundername: ; grantid: 82173280 – fundername: ; grantid: 2021YJ0450 – fundername: ; grantid: 2019-GH02-00036-HZ |
| GroupedDBID | --- 0R~ 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EBD EBLON EBS EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IEA IHR IHW INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP ~8M -5E -5G -A0 -BR 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF NPM PMFND 7X8 PPXIY 5PM PJZUB PUEGO |
| ID | FETCH-LOGICAL-c632t-3f750c353b0a12057a31f2df72c919b748623bfa273c7a2817a0e4679d67d32d3 |
| IEDL.DBID | M48 |
| ISSN | 1756-8722 |
| IngestDate | Wed Aug 27 01:30:22 EDT 2025 Thu Aug 21 18:20:25 EDT 2025 Fri Jul 11 02:48:54 EDT 2025 Tue Jun 17 21:45:16 EDT 2025 Tue Jun 10 20:43:33 EDT 2025 Thu May 22 21:21:37 EDT 2025 Thu Jan 02 22:54:26 EST 2025 Tue Jul 01 04:23:16 EDT 2025 Thu Apr 24 22:58:57 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | PD-L1 regulation Combination therapy Immunotherapy PD-1/PD-L1 |
| Language | English |
| License | 2022. The Author(s). Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c632t-3f750c353b0a12057a31f2df72c919b748623bfa273c7a2817a0e4679d67d32d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://doaj.org/article/48e1f8aff6144c91ab4080684079709a |
| PMID | 35279217 |
| PQID | 2638960445 |
| PQPubID | 23479 |
| PageCount | 58 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_48e1f8aff6144c91ab4080684079709a pubmedcentral_primary_oai_pubmedcentral_nih_gov_8917703 proquest_miscellaneous_2638960445 gale_infotracmisc_A699526041 gale_infotracacademiconefile_A699526041 gale_healthsolutions_A699526041 pubmed_primary_35279217 crossref_primary_10_1186_s13045_022_01242_2 crossref_citationtrail_10_1186_s13045_022_01242_2 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-03-12 |
| PublicationDateYYYYMMDD | 2022-03-12 |
| PublicationDate_xml | – month: 03 year: 2022 text: 2022-03-12 day: 12 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Journal of hematology and oncology |
| PublicationTitleAlternate | J Hematol Oncol |
| PublicationYear | 2022 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | N Spaccarelli (1242_CR82) 2015; 33 G Shi (1242_CR229) 2019; 27 KA Hofmeyer (1242_CR32) 2011; 2011 Y Lan (1242_CR166) 2021; 39 DL Barber (1242_CR67) 2006; 439 K Tanoue (1242_CR251) 2017; 77 SY Tseng (1242_CR28) 2001; 193 A Garcia-Diaz (1242_CR181) 2017; 19 JT Sockolosky (1242_CR298) 2016; 113 S Spranger (1242_CR44) 2013; 5 JT Neal (1242_CR261) 2018; 175 Y Iwai (1242_CR297) 2005; 17 T Oba (1242_CR294) 2020; 11 EA Philips (1242_CR105) 2020; 295 A Lo Cicero (1242_CR99) 2015; 35 Y Doki (1242_CR139) 2022; 386 AJ Schoenfeld (1242_CR124) 2020; 37 J Cai (1242_CR30) 2019; 12 L Holokai (1242_CR267) 2019; 15 H Li (1242_CR236) 2022; 40 C Ghosh (1242_CR1) 2021; 12 CJ Kearney (1242_CR192) 2018; 3 S Suresh (1242_CR279) 2020; 1 K Teruya (1242_CR281) 2019; 17 M Moghanizadeh-Ashkezari (1242_CR210) 2019; 11 Y Ishida (1242_CR16) 1992; 11 J Haanen (1242_CR309) 2018; 29 PA Saunders (1242_CR110) 2005; 35 1242_CR17 T Shinohara (1242_CR26) 1994; 23 L Mazzarella (1242_CR95) 2020; 8 P Zhang (1242_CR276) 2016; 107 CC Foster (1242_CR171) 2021; 27 S Muenst (1242_CR40) 2013; 139 X Dai (1242_CR202) 2021; 81 AB Warner (1242_CR132) 2018; 32 Y Zhang (1242_CR108) 2006; 103 E Marcq (1242_CR117) 2015; 41 HT Lee (1242_CR23) 2019; 24 SL Topalian (1242_CR57) 2017; 318 P Waterhouse (1242_CR304) 1995; 270 Y Gao (1242_CR264) 2021; 6 E Eriksson (1242_CR90) 2019; 202 M Heyner (1242_CR74) 2019; 16 X Zhou (1242_CR129) 2021; 22 L Zhang (1242_CR195) 2020; 12 X Deng (1242_CR80) 2018; 16 S Gettinger (1242_CR125) 2017; 7 AS Bear (1242_CR168) 2020; 38 S Zelenay (1242_CR196) 2015; 162 X Jiang (1242_CR177) 2013; 19 B Colom (1242_CR10) 2021; 598 L Galluzzi (1242_CR146) 2015; 28 J Shen (1242_CR189) 2019; 79 SC Wei (1242_CR70) 2018; 8 AJ Minn (1242_CR128) 2016; 165 A Rawangkan (1242_CR240) 2018; 23 S Champiat (1242_CR307) 2016; 27 S Zuo (1242_CR228) 2021; 9 MC Chen (1242_CR284) 2019; 12 HJ Chon (1242_CR226) 2019; 25 J Wang (1242_CR92) 2017; 36 DH Kim (1242_CR300) 2019; 51 JH Cha (1242_CR203) 2018; 71 F Tsushima (1242_CR65) 2007; 110 SA Patel (1242_CR9) 2018; 48 X Liu (1242_CR109) 2003; 197 HY Li (1242_CR273) 2017; 5 HJ Kim (1242_CR8) 2020; 41 K Koikawa (1242_CR241) 2021; 184 J Zhou (1242_CR52) 2017; 5 M Provencio (1242_CR155) 2020; 21 EA Akbay (1242_CR96) 2013; 3 W Qin (1242_CR113) 2019; 10 K Sakuishi (1242_CR38) 2010; 207 N Wang (1242_CR237) 2020; 30 JM Chinai (1242_CR112) 2015; 36 C Laurent (1242_CR20) 2015; 4 X Jiang (1242_CR31) 2019; 18 I Caffa (1242_CR215) 2020; 583 EJ Wherry (1242_CR50) 2011; 12 T Cascone (1242_CR136) 2021; 27 G Chen (1242_CR292) 2017; 20 TJ Daskivich (1242_CR55) 2015; 67 Y Ban (1242_CR165) 2021; 2 J Rios-Doria (1242_CR282) 2020; 8 Q Sui (1242_CR265) 2021; 9 E Panagioti (1242_CR238) 2021; 131 SK Jabbour (1242_CR156) 2021; 7 EA Hawkes (1242_CR41) 2015; 16 M Wang (1242_CR15) 2019; 1871 Q Liao (1242_CR302) 2020; 8 M Efremova (1242_CR49) 2018; 9 A Martinez-Usatorre (1242_CR206) 2021; 13 C Wan (1242_CR263) 2021; 81 R Clemen (1242_CR289) 2020; 12 T Seto (1242_CR35) 2019; 7 JR Brahmer (1242_CR56) 2012; 366 CJ Langer (1242_CR148) 2016; 17 S Kleffel (1242_CR72) 2015; 162 KC Lam (1242_CR214) 2021; 184 EE Vokes (1242_CR312) 2018; 29 T Fujisawa (1242_CR288) 2019; 10 S Stevanovic (1242_CR220) 2015; 33 G Kroemer (1242_CR123) 2015; 4 L Holokai (1242_CR260) 2020; 12 Y Li (1242_CR278) 2018; 6 B Gong (1242_CR280) 2019; 216 SF Bakhoum (1242_CR184) 2018; 174 S Sun (1242_CR5) 2021; 13 MA Hossain (1242_CR3) 2021; 41 V Koh (1242_CR259) 2021; 518 F Haderk (1242_CR102) 2017; 2 C Viricel (1242_CR104) 2015; 57 LV Riella (1242_CR37) 2012; 12 M Song (1242_CR176) 2013; 8 W Theelen (1242_CR170) 2019; 5 JH Yearley (1242_CR106) 2017; 23 C Wang (1242_CR293) 2021; 268 RH Thompson (1242_CR45) 2006; 66 M-N Theodoraki (1242_CR53) 2018; 24 SO Lim (1242_CR239) 2016; 30 F Voli (1242_CR179) 2020; 80 RM Chabanon (1242_CR235) 2021; 21 EA Said (1242_CR21) 2010; 16 P Schmid (1242_CR149) 2018; 379 L Karapetyan (1242_CR201) 2020; 13 S Jin (1242_CR244) 2020; 59 Y Zhang (1242_CR254) 2019; 20 L Galluzzi (1242_CR142) 2017; 17 HQ Mai (1242_CR160) 2022; 28 A Passaro (1242_CR137) 2021; 22 L Guo (1242_CR245) 2021; 279 A Pircher (1242_CR173) 2014; 85 M Wang (1242_CR61) 2017; 8 X Jiang (1242_CR275) 2020; 10 NJ Llosa (1242_CR122) 2015; 5 D Mathios (1242_CR147) 2016; 8 P Li (1242_CR191) 2019; 202 N Li (1242_CR204) 2018; 67 D Yee (1242_CR86) 2017; 292 YY Janjigian (1242_CR157) 2021; 600 Y Zhang (1242_CR151) 2021; 39 C Glorieux (1242_CR97) 2021; 38 L Heim (1242_CR253) 2018; 78 KJ Lastwika (1242_CR175) 2016; 76 M Nishio (1242_CR161) 2021; 16 A Grenda (1242_CR194) 2019; 17 ME Keir (1242_CR29) 2008; 26 D Bommarito (1242_CR77) 2017; 188 M Simian (1242_CR256) 2017; 216 J Kwon (1242_CR183) 2020; 10 M Verduin (1242_CR257) 2021; 11 L Gandhi (1242_CR130) 2018; 378 LM Francisco (1242_CR25) 2010; 236 J Galon (1242_CR131) 2019; 18 Y Wang (1242_CR246) 2021; 33 E Sato (1242_CR13) 2005; 102 RM Hanna (1242_CR205) 2020; 8 J Fu (1242_CR211) 2020; 131 J Vincent (1242_CR144) 2010; 70 S Sun (1242_CR39) 2014; 63 C Geuijen (1242_CR250) 2021; 12 AP Bally (1242_CR76) 2017; 198 T Sen (1242_CR186) 2019; 9 KS Sfanos (1242_CR46) 2009; 69 AM Frederickson (1242_CR313) 2019; 11 H Bo (1242_CR84) 2018; 9 R Mao (1242_CR274) 2020; 111 J Li (1242_CR93) 2019; 15 K Guzik (1242_CR24) 2019; 24 S Jaiswal (1242_CR188) 2009; 138 KM Zak (1242_CR22) 2017; 25 RL Maute (1242_CR270) 2015; 112 H Soliman (1242_CR47) 2014; 9 JM Chemnitz (1242_CR116) 2004; 173 Y Wang (1242_CR198) 2021; 39 HA Tawbi (1242_CR140) 2021; 22 CV Dang (1242_CR187) 2012; 149 B Liu (1242_CR271) 2019; 99 A Baggiolini (1242_CR11) 2021; 373 H Wang (1242_CR283) 2020; 39 JP Wang (1242_CR60) 2017; 9 K Lei (1242_CR230) 2021; 5 JM Boland (1242_CR43) 2013; 14 HK Hong (1242_CR262) 2021; 10 LP Kane (1242_CR114) 2003; 192 Y Wang (1242_CR91) 2018; 17 A Steven (1242_CR135) 2016; 21 X Li (1242_CR208) 2019; 8 X Qiu (1242_CR242) 2021; 81 J Chakrabarti (1242_CR303) 2018; 1817 AA Tarhini (1242_CR19) 2015; 13 CW Li (1242_CR243) 2018; 33 E Tran (1242_CR221) 2016; 375 HL Kaufman (1242_CR227) 2015; 14 H Li (1242_CR247) 2021; 8 EA Tivol (1242_CR305) 1995; 3 SY Wu (1242_CR182) 2021; 9 W Gu (1242_CR100) 2019; 46 F Barlesi (1242_CR311) 2019; 14 HY Cho (1242_CR78) 2008; 1779 X Zhang (1242_CR291) 2019; 16 X Gong (1242_CR163) 2017; 12 T Gargett (1242_CR224) 2016; 24 Z Xiang (1242_CR268) 2021; 40 T Wartewig (1242_CR34) 2017; 552 H Valadi (1242_CR98) 2007; 9 GJ Freeman (1242_CR75) 2000; 192 BGL Vanneste (1242_CR164) 2020; 9 X Lu (1242_CR197) 2017; 543 R Rosenthal (1242_CR127) 2019; 567 FF Chen (1242_CR286) 2020; 9 WJ Ho (1242_CR12) 2021; 373 H Sumimoto (1242_CR193) 2016; 11 CM Della Corte (1242_CR266) 2019; 38 F Zheng (1242_CR290) 2017; 2017 G Chen (1242_CR51) 2018; 560 N Zhang (1242_CR87) 2016; 49 F Martins (1242_CR316) 2019; 16 S Lu (1242_CR287) 2021; 112 G Fromm (1242_CR296) 2018; 6 N Patsoukis (1242_CR33) 2013; 33 L Jiang (1242_CR299) 2019; 9 BC Creelan (1242_CR223) 2021; 27 W Wang (1242_CR145) 2016; 165 A Addeo (1242_CR217) 2019; 9 Y Zheng (1242_CR285) 2019; 18 MA Postow (1242_CR315) 2018; 378 DS Chen (1242_CR54) 2017; 541 LM Francisco (1242_CR68) 2009; 206 TK Eigentler (1242_CR308) 2016; 45 ZR Huinen (1242_CR207) 2021; 18 Y Liu (1242_CR48) 2013; 33 X Wang (1242_CR85) 2017; 184 RA Luchtel (1242_CR213) 2020; 117 A Kumar (1242_CR295) 2020; 9 JJ Zhao (1242_CR158) 2022; 40 JE Long (1242_CR233) 2016; 34 JM Jubel (1242_CR36) 2020; 11 EW Weber (1242_CR81) 2021; 372 T Azuma (1242_CR71) 2008; 111 L Cao (1242_CR2) 2021; 10 N Selenko-Gebauer (1242_CR64) 2003; 170 C Zhou (1242_CR159) 2022; 23 S Spranger (1242_CR190) 2016; 26 D Ciardiello (1242_CR167) 2019; 76 AR Parikh (1242_CR169) 2021; 2 S Kim (1242_CR162) 2017; 99 FS Hodi (1242_CR306) 2003; 100 B Liu (1242_CR58) 2017; 10 H Yousefi (1242_CR174) 2017; 13 A Marabelle (1242_CR200) 2017; 28 H Jiang (1242_CR252) 2021; 10 R Rekik (1242_CR73) 2015; 12 A Magri (1242_CR212) 2020; 12 M Nishino (1242_CR119) 2017; 14 D Miles (1242_CR150) 2021; 32 Y Latchman (1242_CR103) 2001; 2 MJ Shen (1242_CR88) 2017; 8 H Dong (1242_CR27) 1999; 5 Z Qi (1242_CR199) 2022; 13 DC Qian (1242_CR232) 2021; 22 JA Thompson (1242_CR314) 2018; 16 DS Chen (1242_CR14) 2013; 39 S Terawaki (1242_CR79) 2011; 186 PM Forde (1242_CR172) 2018; 378 1242_CR141 F Wei (1242_CR59) 2018; 118 1242_CR133 M Marasco (1242_CR115) 2020; 6 1242_CR138 J Chakrabarti (1242_CR258) 2021; 13 Q Yang (1242_CR152) 2020; 10 H Zhang (1242_CR216) 2021; 8 S Budhu (1242_CR7) 2021; 34 JM Pitt (1242_CR4) 2016; 44 S Majo (1242_CR63) 2021; 13 SA Rosenberg (1242_CR218) 2011; 17 MS Shajib (1242_CR248) 2015; 213 K Gabrusiewicz (1242_CR101) 2018; 7 C Shao (1242_CR62) 2018; 17 J Galon (1242_CR120) 2006; 313 S Rafiq (1242_CR225) 2018; 36 KJ Mackenzie (1242_CR185) 2017; 548 L Apetoh (1242_CR143) 2007; 220 JW Kjeldsen (1242_CR231) 2021; 27 D Sarrouilhe (1242_CR249) 2019; 161 C Hinterleitner (1242_CR301) 2021; 12 1242_CR269 J Gao (1242_CR126) 2016; 167 A Alsuliman (1242_CR180) 2015; 14 L Fehrenbacher (1242_CR310) 2016; 387 N Messal (1242_CR107) 2011; 48 N Zacharakis (1242_CR222) 2018; 24 B Bengsch (1242_CR66) 2016; 45 SC Casey (1242_CR94) 2016; 352 C Liu (1242_CR272) 2020; 470 E Felip (1242_CR154) 2021; 398 L Xu (1242_CR89) 2018; 12 L Paz-Ares (1242_CR153) 2020; 15 N Chen (1242_CR178) 2015; 10 J Krueger (1242_CR255) 2021; 16 AH Sharpe (1242_CR18) 2007; 8 H Ma (1242_CR209) 2019; 120 1242_CR277 N Sehrawat (1242_CR6) 2021; 70 S Yao (1242_CR69) 2009; 113 MT Villanueva (1242_CR118) 2017; 17 M Mandai (1242_CR83) 2016; 22 GL Re (1242_CR234) 2020; 128 E Tran (1242_CR219) 2014; 344 V Velcheti (1242_CR42) 2014; 94 K Bardhan (1242_CR111) 2016; 7 E Vacchelli (1242_CR134) 2015; 350 SL Topalian (1242_CR121) 2012; 366 |
| References_xml | – volume: 39 start-page: 1375 year: 2021 ident: 1242_CR198 publication-title: Cancer Cell doi: 10.1016/j.ccell.2021.07.023 – volume: 184 start-page: 4753 year: 2021 ident: 1242_CR241 publication-title: Cell doi: 10.1016/j.cell.2021.07.020 – volume: 23 start-page: 220 year: 2022 ident: 1242_CR159 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(21)00650-1 – volume: 17 start-page: 5193 year: 2019 ident: 1242_CR194 publication-title: Oncol Lett – volume: 24 start-page: 896 year: 2018 ident: 1242_CR53 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-17-2664 – volume: 33 start-page: 3091 year: 2013 ident: 1242_CR33 publication-title: Mol Cell Biol doi: 10.1128/MCB.00319-13 – volume: 94 start-page: 107 year: 2014 ident: 1242_CR42 publication-title: Lab Investig doi: 10.1038/labinvest.2013.130 – volume: 8 start-page: e65821 year: 2013 ident: 1242_CR176 publication-title: PLoS ONE doi: 10.1371/journal.pone.0065821 – volume: 9 start-page: 12487 year: 2017 ident: 1242_CR60 publication-title: Oncotarget doi: 10.18632/oncotarget.23552 – volume: 80 start-page: 4129 year: 2020 ident: 1242_CR179 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-20-0471 – volume: 165 start-page: 272 year: 2016 ident: 1242_CR128 publication-title: Cell doi: 10.1016/j.cell.2016.03.031 – volume: 12 start-page: 3575 year: 2020 ident: 1242_CR289 publication-title: Cancers (Basel) doi: 10.3390/cancers12123575 – volume: 29 start-page: 959 year: 2018 ident: 1242_CR312 publication-title: Ann Oncol doi: 10.1093/annonc/mdy041 – volume: 8 start-page: e000475 year: 2020 ident: 1242_CR95 publication-title: J Immunother Cancer doi: 10.1136/jitc-2019-000475 – volume: 167 start-page: 397 year: 2016 ident: 1242_CR126 publication-title: Cell doi: 10.1016/j.cell.2016.08.069 – volume: 29 start-page: iv264 year: 2018 ident: 1242_CR309 publication-title: Ann Oncol doi: 10.1093/annonc/mdy162 – volume: 2 start-page: eaah5509 year: 2017 ident: 1242_CR102 publication-title: Sci Immunol doi: 10.1126/sciimmunol.aah5509 – volume: 32 start-page: 228 year: 2018 ident: 1242_CR132 publication-title: Oncology (Williston Park) – volume: 6 start-page: 398 year: 2021 ident: 1242_CR264 publication-title: Signal Transduct Target Ther doi: 10.1038/s41392-021-00795-x – volume: 33 start-page: 14231 year: 2013 ident: 1242_CR48 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.5812-12.2013 – volume: 38 start-page: 101780 year: 2021 ident: 1242_CR97 publication-title: Redox Biol doi: 10.1016/j.redox.2020.101780 – volume: 175 start-page: 1972 year: 2018 ident: 1242_CR261 publication-title: Cell doi: 10.1016/j.cell.2018.11.021 – volume: 79 start-page: 311 year: 2019 ident: 1242_CR189 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-18-1003 – volume: 373 start-page: 1306 year: 2021 ident: 1242_CR12 publication-title: Science doi: 10.1126/science.abl5376 – volume: 13 start-page: eabd1616 year: 2021 ident: 1242_CR206 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.abd1616 – volume: 27 start-page: 244 year: 2019 ident: 1242_CR229 publication-title: Mol Ther doi: 10.1016/j.ymthe.2018.11.010 – volume: 30 start-page: 2004940 year: 2020 ident: 1242_CR237 publication-title: Adv Funct Mat doi: 10.1002/adfm.202004940 – volume: 18 start-page: 527 year: 2021 ident: 1242_CR207 publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-021-00496-y – volume: 22 start-page: 1265 year: 2021 ident: 1242_CR129 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(21)00333-8 – volume: 2017 start-page: 1293201 year: 2017 ident: 1242_CR290 publication-title: Biomed Res Int doi: 10.1155/2017/1293201 – volume: 110 start-page: 180 year: 2007 ident: 1242_CR65 publication-title: Blood doi: 10.1182/blood-2006-11-060087 – volume: 8 start-page: 80506 year: 2017 ident: 1242_CR88 publication-title: Oncotarget doi: 10.18632/oncotarget.19193 – volume: 99 start-page: 307 year: 2019 ident: 1242_CR271 publication-title: Acta Biomater doi: 10.1016/j.actbio.2019.08.046 – volume: 14 start-page: 157 year: 2013 ident: 1242_CR43 publication-title: Clin Lung Cancer doi: 10.1016/j.cllc.2012.05.006 – volume: 41 start-page: 948 year: 2020 ident: 1242_CR8 publication-title: Trends Immunol doi: 10.1016/j.it.2020.08.010 – volume: 24 start-page: 1135 year: 2016 ident: 1242_CR224 publication-title: Mol Ther doi: 10.1038/mt.2016.63 – volume: 198 start-page: 205 year: 2017 ident: 1242_CR76 publication-title: J Immunol doi: 10.4049/jimmunol.1601464 – volume: 16 start-page: 392 year: 2019 ident: 1242_CR291 publication-title: Cell Mol Immunol doi: 10.1038/s41423-018-0021-3 – volume: 17 start-page: 97 year: 2017 ident: 1242_CR142 publication-title: Nat Rev Immunol doi: 10.1038/nri.2016.107 – volume: 13 start-page: 182 year: 2022 ident: 1242_CR199 publication-title: Nat Commun doi: 10.1038/s41467-021-27833-0 – volume: 13 start-page: 1001 year: 2017 ident: 1242_CR174 publication-title: Expert Rev Clin Immunol doi: 10.1080/1744666X.2017.1366315 – volume: 7 start-page: 1 year: 2021 ident: 1242_CR156 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2021.2301 – volume: 99 start-page: E602-E3 year: 2017 ident: 1242_CR162 publication-title: Int J Radiat Oncol Biol Phys doi: 10.1016/j.ijrobp.2017.06.2051 – volume: 33 start-page: e2103497 year: 2021 ident: 1242_CR246 publication-title: Adv Mater doi: 10.1002/adma.202103497 – volume: 12 start-page: 648 year: 2015 ident: 1242_CR73 publication-title: Cell Mol Immunol doi: 10.1038/cmi.2014.104 – volume: 17 start-page: 4550 year: 2011 ident: 1242_CR218 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-0116 – volume: 20 start-page: 164 year: 2019 ident: 1242_CR254 publication-title: Respir Res doi: 10.1186/s12931-019-1137-4 – volume: 268 start-page: 120579 year: 2021 ident: 1242_CR293 publication-title: Biomaterials doi: 10.1016/j.biomaterials.2020.120579 – volume: 35 start-page: 69 year: 2015 ident: 1242_CR99 publication-title: Curr Opin Cell Biol doi: 10.1016/j.ceb.2015.04.013 – volume: 10 start-page: 2298 year: 2019 ident: 1242_CR113 publication-title: Front Immunol doi: 10.3389/fimmu.2019.02298 – volume: 18 start-page: 5399 year: 2019 ident: 1242_CR285 publication-title: Oncol Lett – volume: 5 start-page: 200ra116 year: 2013 ident: 1242_CR44 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.3006504 – volume: 118 start-page: 233 year: 2018 ident: 1242_CR59 publication-title: Br J Cancer doi: 10.1038/bjc.2017.385 – volume: 28 start-page: 214 year: 2022 ident: 1242_CR160 publication-title: Nat Med doi: 10.1038/s41591-021-01673-3 – volume: 161 start-page: 46 year: 2019 ident: 1242_CR249 publication-title: Biochimie doi: 10.1016/j.biochi.2018.06.016 – volume: 66 start-page: 3381 year: 2006 ident: 1242_CR45 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-4303 – volume: 17 start-page: 133 year: 2005 ident: 1242_CR297 publication-title: Int Immunol doi: 10.1093/intimm/dxh194 – volume: 78 start-page: 3619 year: 2018 ident: 1242_CR253 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-17-3297 – volume: 16 start-page: 653 year: 2021 ident: 1242_CR161 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2020.11.025 – volume: 16 start-page: 101 year: 2019 ident: 1242_CR74 publication-title: Cell Mol Immunol doi: 10.1038/s41423-018-0176-y – volume: 111 start-page: 3635 year: 2008 ident: 1242_CR71 publication-title: Blood doi: 10.1182/blood-2007-11-123141 – volume: 24 start-page: 1190 year: 2019 ident: 1242_CR23 publication-title: Molecules doi: 10.3390/molecules24061190 – volume: 8 start-page: 2001596 year: 2021 ident: 1242_CR247 publication-title: Adv Sci (Weinh) doi: 10.1002/advs.202001596 – volume: 107 start-page: 1563 year: 2016 ident: 1242_CR276 publication-title: Cancer Sci doi: 10.1111/cas.13072 – volume: 5 start-page: 1365 year: 1999 ident: 1242_CR27 publication-title: Nat Med doi: 10.1038/70932 – volume: 9 start-page: 4677 year: 2018 ident: 1242_CR84 publication-title: J Cancer doi: 10.7150/jca.26461 – volume: 39 start-page: 1 year: 2013 ident: 1242_CR14 publication-title: Immunity doi: 10.1016/j.immuni.2013.07.012 – volume: 113 start-page: E2646 year: 2016 ident: 1242_CR298 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1604268113 – volume: 70 start-page: 3052 year: 2010 ident: 1242_CR144 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-09-3690 – volume: 39 start-page: 29 year: 2020 ident: 1242_CR283 publication-title: J Exp Clin Cancer Res CR doi: 10.1186/s13046-020-1536-x – volume: 28 start-page: xii33 year: 2017 ident: 1242_CR200 publication-title: Ann Oncol doi: 10.1093/annonc/mdx683 – volume: 10 start-page: 910 year: 2015 ident: 1242_CR178 publication-title: J Thorac Oncol doi: 10.1097/JTO.0000000000000500 – volume: 10 start-page: 174 year: 2017 ident: 1242_CR58 publication-title: J Hematol Oncol doi: 10.1186/s13045-017-0541-9 – volume: 71 start-page: 606 year: 2018 ident: 1242_CR203 publication-title: Mol Cell doi: 10.1016/j.molcel.2018.07.030 – volume: 40 start-page: 36 year: 2022 ident: 1242_CR236 publication-title: Cancer Cell doi: 10.1016/j.ccell.2021.11.002 – volume: 39 start-page: 1578 issue: 12 year: 2021 ident: 1242_CR151 publication-title: Cancer Cell doi: 10.1016/j.ccell.2021.09.010 – volume: 13 start-page: 319 year: 2015 ident: 1242_CR19 publication-title: J Transl Med doi: 10.1186/s12967-015-0678-7 – volume: 45 start-page: 358 year: 2016 ident: 1242_CR66 publication-title: Immunity doi: 10.1016/j.immuni.2016.07.008 – volume: 113 start-page: 5811 year: 2009 ident: 1242_CR69 publication-title: Blood doi: 10.1182/blood-2009-02-203141 – volume: 13 start-page: 1639 year: 2021 ident: 1242_CR5 publication-title: Cancers (Basel) doi: 10.3390/cancers13071639 – volume: 598 start-page: 510 year: 2021 ident: 1242_CR10 publication-title: Nature doi: 10.1038/s41586-021-03965-7 – volume: 470 start-page: 95 year: 2020 ident: 1242_CR272 publication-title: Cancer Lett doi: 10.1016/j.canlet.2019.10.027 – volume: 19 start-page: 598 year: 2013 ident: 1242_CR177 publication-title: Clin Cancer Res Off J Am Assoc Cancer Res doi: 10.1158/1078-0432.CCR-12-2731 – volume: 51 start-page: 1 year: 2019 ident: 1242_CR300 publication-title: Exp Mol Med – volume: 139 start-page: 667 year: 2013 ident: 1242_CR40 publication-title: Breast Cancer Res Treat doi: 10.1007/s10549-013-2581-3 – volume: 44 start-page: 1255 year: 2016 ident: 1242_CR4 publication-title: Immunity doi: 10.1016/j.immuni.2016.06.001 – volume: 14 start-page: 655 year: 2017 ident: 1242_CR119 publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2017.88 – volume: 184 start-page: 5338 year: 2021 ident: 1242_CR214 publication-title: Cell doi: 10.1016/j.cell.2021.09.019 – volume: 12 start-page: eaaz5387 year: 2020 ident: 1242_CR195 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aaz5387 – volume: 112 start-page: 1878 year: 2021 ident: 1242_CR287 publication-title: Cancer Sci doi: 10.1111/cas.14844 – volume: 48 start-page: 2214 year: 2011 ident: 1242_CR107 publication-title: Mol Immunol doi: 10.1016/j.molimm.2011.06.436 – volume: 17 start-page: 1497 year: 2016 ident: 1242_CR148 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30498-3 – volume: 313 start-page: 1960 year: 2006 ident: 1242_CR120 publication-title: Science doi: 10.1126/science.1129139 – volume: 366 start-page: 2443 year: 2012 ident: 1242_CR121 publication-title: N Engl J Med doi: 10.1056/NEJMoa1200690 – volume: 165 start-page: 1092 year: 2016 ident: 1242_CR145 publication-title: Cell doi: 10.1016/j.cell.2016.04.009 – volume: 17 start-page: 1457 year: 2018 ident: 1242_CR91 publication-title: Cell Cycle doi: 10.1080/15384101.2018.1489177 – ident: 1242_CR269 doi: 10.1136/jitc-2021-003213 – volume: 162 start-page: 1242 year: 2015 ident: 1242_CR72 publication-title: Cell doi: 10.1016/j.cell.2015.08.052 – volume: 41 start-page: 156 year: 2021 ident: 1242_CR3 publication-title: Med Res Rev doi: 10.1002/med.21727 – volume: 373 start-page: eabc1048 year: 2021 ident: 1242_CR11 publication-title: Science doi: 10.1126/science.abc1048 – volume: 5 start-page: 1276 year: 2019 ident: 1242_CR170 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2019.1478 – volume: 10 start-page: 139 year: 2020 ident: 1242_CR275 publication-title: Cell Biosci doi: 10.1186/s13578-020-00499-9 – volume: 11 start-page: 407 year: 2019 ident: 1242_CR313 publication-title: Immunotherapy doi: 10.2217/imt-2018-0193 – volume: 117 start-page: 1666 year: 2020 ident: 1242_CR213 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1908158117 – volume: 2 start-page: 1124 year: 2021 ident: 1242_CR169 publication-title: Nat Cancer doi: 10.1038/s43018-021-00269-7 – volume: 22 start-page: 2329 year: 2016 ident: 1242_CR83 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-0224 – volume: 279 start-page: 119359 year: 2021 ident: 1242_CR245 publication-title: Life Sci doi: 10.1016/j.lfs.2021.119359 – volume: 8 start-page: 239 year: 2007 ident: 1242_CR18 publication-title: Nat Immunol doi: 10.1038/ni1443 – volume: 3 start-page: 541 year: 1995 ident: 1242_CR305 publication-title: Immunity doi: 10.1016/1074-7613(95)90125-6 – volume: 4 start-page: e1026530 year: 2015 ident: 1242_CR20 publication-title: Oncoimmunology doi: 10.1080/2162402X.2015.1026530 – volume: 25 start-page: 1612 year: 2019 ident: 1242_CR226 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-18-1932 – volume: 344 start-page: 641 year: 2014 ident: 1242_CR219 publication-title: Science doi: 10.1126/science.1251102 – volume: 10 start-page: 8382 year: 2020 ident: 1242_CR152 publication-title: Theranostics doi: 10.7150/thno.45391 – volume: 17 start-page: 511 year: 2017 ident: 1242_CR118 publication-title: Nat Rev Cancer doi: 10.1038/nrc.2017.75 – volume: 366 start-page: 2455 year: 2012 ident: 1242_CR56 publication-title: N Engl J Med doi: 10.1056/NEJMoa1200694 – volume: 35 start-page: 3561 year: 2005 ident: 1242_CR110 publication-title: Eur J Immunol doi: 10.1002/eji.200526347 – volume: 174 start-page: 1347 year: 2018 ident: 1242_CR184 publication-title: Cell doi: 10.1016/j.cell.2018.08.027 – volume: 23 start-page: 704 year: 1994 ident: 1242_CR26 publication-title: Genomics doi: 10.1006/geno.1994.1562 – volume: 33 start-page: 731 year: 2015 ident: 1242_CR82 publication-title: Dermatol Clin doi: 10.1016/j.det.2015.05.008 – volume: 40 start-page: 392 year: 2022 ident: 1242_CR158 publication-title: J Clin Oncol doi: 10.1200/JCO.21.01862 – volume: 2011 start-page: 1 year: 2011 ident: 1242_CR32 publication-title: J Biomed Biotechnol doi: 10.1155/2011/451694 – volume: 192 start-page: 1027 year: 2000 ident: 1242_CR75 publication-title: J Exp Med doi: 10.1084/jem.192.7.1027 – volume: 16 start-page: 452 year: 2010 ident: 1242_CR21 publication-title: Nat Med doi: 10.1038/nm.2106 – volume: 11 start-page: 5415 year: 2020 ident: 1242_CR294 publication-title: Nat Commun doi: 10.1038/s41467-020-19192-z – volume: 76 start-page: 22 year: 2019 ident: 1242_CR167 publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2019.04.003 – volume: 8 start-page: 370ra180 year: 2016 ident: 1242_CR147 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aag2942 – volume: 67 start-page: 816 year: 2015 ident: 1242_CR55 publication-title: Eur Urol doi: 10.1016/j.eururo.2014.12.052 – volume: 6 start-page: eaay4458 year: 2020 ident: 1242_CR115 publication-title: Sci Adv doi: 10.1126/sciadv.aay4458 – volume: 378 start-page: 2078 year: 2018 ident: 1242_CR130 publication-title: N Engl J Med doi: 10.1056/NEJMoa1801005 – volume: 38 start-page: 788 year: 2020 ident: 1242_CR168 publication-title: Cancer Cell doi: 10.1016/j.ccell.2020.08.004 – volume: 7 start-page: e1412909 year: 2018 ident: 1242_CR101 publication-title: Oncoimmunology doi: 10.1080/2162402X.2017.1412909 – volume: 9 start-page: e88557 year: 2014 ident: 1242_CR47 publication-title: PLoS ONE doi: 10.1371/journal.pone.0088557 – volume: 543 start-page: 728 year: 2017 ident: 1242_CR197 publication-title: Nature doi: 10.1038/nature21676 – volume: 131 start-page: 110588 year: 2020 ident: 1242_CR211 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2020.110588 – volume: 216 start-page: 31 year: 2017 ident: 1242_CR256 publication-title: J Cell Biol doi: 10.1083/jcb.201610056 – volume: 9 start-page: 3705 year: 2019 ident: 1242_CR299 publication-title: Sci Rep doi: 10.1038/s41598-018-38068-3 – volume: 518 start-page: 59 year: 2021 ident: 1242_CR259 publication-title: Cancer Lett doi: 10.1016/j.canlet.2021.06.007 – volume: 16 start-page: e234 year: 2015 ident: 1242_CR41 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(15)70103-8 – volume: 100 start-page: 4712 year: 2003 ident: 1242_CR306 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0830997100 – ident: 1242_CR141 doi: 10.1200/JCO.21.02067 – volume: 9 start-page: e002528 year: 2021 ident: 1242_CR182 publication-title: J Immunother Cancer doi: 10.1136/jitc-2021-002528 – volume: 11 start-page: 35525 year: 2019 ident: 1242_CR210 publication-title: ACS Appl Mater Interfaces doi: 10.1021/acsami.9b07556 – volume: 16 start-page: 594 year: 2018 ident: 1242_CR314 publication-title: J Natl Compr Cancer Netw doi: 10.6004/jnccn.2018.0047 – ident: 1242_CR17 doi: 10.1007/s00262-021-03130-z – ident: 1242_CR133 doi: 10.1158/2159-8290.CD-RW2018-017 – volume: 552 start-page: 121 year: 2017 ident: 1242_CR34 publication-title: Nature doi: 10.1038/nature24649 – volume: 77 start-page: 2040 year: 2017 ident: 1242_CR251 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-16-1577 – volume: 23 start-page: 2071 year: 2018 ident: 1242_CR240 publication-title: Molecules doi: 10.3390/molecules23082071 – volume: 6 start-page: 31 year: 2018 ident: 1242_CR278 publication-title: J Immunother Cancer doi: 10.1186/s40425-018-0329-7 – volume: 9 start-page: e002843 year: 2021 ident: 1242_CR228 publication-title: J Immunother Cancer doi: 10.1136/jitc-2021-002843 – volume: 9 start-page: e52330 year: 2020 ident: 1242_CR295 publication-title: Elife doi: 10.7554/eLife.52330 – volume: 12 start-page: 7005 year: 2021 ident: 1242_CR301 publication-title: Nat Commun doi: 10.1038/s41467-021-27303-7 – volume: 10 start-page: 391 year: 2019 ident: 1242_CR288 publication-title: Mol Clin Oncol – volume: 7 start-page: 14 year: 2019 ident: 1242_CR35 publication-title: Med Sci (Basel) – volume: 70 start-page: 24 year: 2021 ident: 1242_CR6 publication-title: Semin Cancer Biol doi: 10.1016/j.semcancer.2020.06.009 – volume: 12 start-page: 3816 year: 2020 ident: 1242_CR260 publication-title: Cancers (Basel) doi: 10.3390/cancers12123816 – volume: 39 start-page: 1388 year: 2021 ident: 1242_CR166 publication-title: Cancer Cell doi: 10.1016/j.ccell.2021.08.008 – volume: 3 start-page: eaar3451 year: 2018 ident: 1242_CR192 publication-title: Sci Immunol doi: 10.1126/sciimmunol.aar3451 – volume: 295 start-page: 4372 year: 2020 ident: 1242_CR105 publication-title: J Biol Chem doi: 10.1074/jbc.AC119.011747 – volume: 1817 start-page: 157 year: 2018 ident: 1242_CR303 publication-title: Methods Mol Biol (Clifton, NJ) doi: 10.1007/978-1-4939-8600-2_16 – volume: 193 start-page: 839 year: 2001 ident: 1242_CR28 publication-title: J Exp Med doi: 10.1084/jem.193.7.839 – volume: 378 start-page: 1976 year: 2018 ident: 1242_CR172 publication-title: N Engl J Med doi: 10.1056/NEJMoa1716078 – volume: 8 start-page: e000416 year: 2020 ident: 1242_CR282 publication-title: J Immunother Cancer doi: 10.1136/jitc-2019-000416 – volume: 8 start-page: 2003404 year: 2021 ident: 1242_CR216 publication-title: Adv Sci (Weinh) doi: 10.1002/advs.202003404 – volume: 541 start-page: 321 year: 2017 ident: 1242_CR54 publication-title: Nature doi: 10.1038/nature21349 – volume: 23 start-page: 3158 year: 2017 ident: 1242_CR106 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-1761 – volume: 15 start-page: 1667 year: 2019 ident: 1242_CR93 publication-title: Future Oncol (Lond, Engl) doi: 10.2217/fon-2018-0639 – volume: 350 start-page: 972 year: 2015 ident: 1242_CR134 publication-title: Science doi: 10.1126/science.aad0779 – volume: 548 start-page: 461 year: 2017 ident: 1242_CR185 publication-title: Nature doi: 10.1038/nature23449 – volume: 9 start-page: 264 year: 2019 ident: 1242_CR217 publication-title: Front Oncol doi: 10.3389/fonc.2019.00264 – volume: 102 start-page: 18538 year: 2005 ident: 1242_CR13 publication-title: Proc Natl Acad Sci USA doi: 10.1073/pnas.0509182102 – volume: 85 start-page: 81 year: 2014 ident: 1242_CR173 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2014.04.001 – volume: 2 start-page: 261 year: 2001 ident: 1242_CR103 publication-title: Nat Immunol doi: 10.1038/85330 – volume: 81 start-page: 2317 year: 2021 ident: 1242_CR202 publication-title: Mol Cell doi: 10.1016/j.molcel.2021.03.037 – volume: 10 start-page: 1943180 year: 2021 ident: 1242_CR252 publication-title: Oncoimmunology doi: 10.1080/2162402X.2021.1943180 – volume: 9 start-page: e001498 year: 2021 ident: 1242_CR265 publication-title: J Immunother Cancer doi: 10.1136/jitc-2020-001498 – volume: 9 start-page: 1831153 year: 2020 ident: 1242_CR286 publication-title: Oncoimmunology doi: 10.1080/2162402X.2020.1831153 – volume: 22 start-page: 157 year: 2021 ident: 1242_CR137 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30701-4 – volume: 398 start-page: 1344 year: 2021 ident: 1242_CR154 publication-title: Lancet (London, England) doi: 10.1016/S0140-6736(21)02098-5 – volume: 19 start-page: 1189 year: 2017 ident: 1242_CR181 publication-title: Cell Rep doi: 10.1016/j.celrep.2017.04.031 – volume: 21 start-page: 701 year: 2021 ident: 1242_CR235 publication-title: Nat Rev Cancer doi: 10.1038/s41568-021-00386-6 – volume: 20 start-page: 917 year: 2017 ident: 1242_CR292 publication-title: Nat Neurosci doi: 10.1038/nn.4571 – volume: 12 start-page: 8437 year: 2019 ident: 1242_CR30 publication-title: Onco Targets Ther doi: 10.2147/OTT.S221340 – volume: 8 start-page: 1069 year: 2018 ident: 1242_CR70 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-18-0367 – volume: 18 start-page: 197 year: 2019 ident: 1242_CR131 publication-title: Nat Rev Drug Discov doi: 10.1038/s41573-018-0007-y – volume: 32 start-page: 994 year: 2021 ident: 1242_CR150 publication-title: Ann Oncol doi: 10.1016/j.annonc.2021.05.801 – volume: 30 start-page: 925 year: 2016 ident: 1242_CR239 publication-title: Cancer Cell doi: 10.1016/j.ccell.2016.10.010 – volume: 63 start-page: 395 year: 2014 ident: 1242_CR39 publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-014-1519-x – volume: 27 start-page: 504 year: 2021 ident: 1242_CR136 publication-title: Nat Med doi: 10.1038/s41591-020-01224-2 – volume: 162 start-page: 1257 year: 2015 ident: 1242_CR196 publication-title: Cell doi: 10.1016/j.cell.2015.08.015 – volume: 12 start-page: 57 year: 2019 ident: 1242_CR284 publication-title: Cancers (Basel) doi: 10.3390/cancers12010057 – volume: 27 start-page: 559 year: 2016 ident: 1242_CR307 publication-title: Ann Oncol Off J Eur Soc Med Oncol doi: 10.1093/annonc/mdv623 – volume: 11 start-page: 3887 year: 1992 ident: 1242_CR16 publication-title: EMBO J doi: 10.1002/j.1460-2075.1992.tb05481.x – volume: 220 start-page: 47 year: 2007 ident: 1242_CR143 publication-title: Immunol Rev doi: 10.1111/j.1600-065X.2007.00573.x – volume: 8 start-page: 2050313X2090703 year: 2020 ident: 1242_CR205 publication-title: SAGE Open Med Case Rep doi: 10.1177/2050313X20907033 – volume: 202 start-page: 787 year: 2019 ident: 1242_CR90 publication-title: J Immunol doi: 10.4049/jimmunol.1800717 – volume: 36 start-page: 847 year: 2018 ident: 1242_CR225 publication-title: Nat Biotechnol doi: 10.1038/nbt.4195 – volume: 36 start-page: 6235 year: 2017 ident: 1242_CR92 publication-title: Oncogene doi: 10.1038/onc.2017.217 – volume: 12 start-page: eaay8707 year: 2020 ident: 1242_CR212 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.aay8707 – volume: 21 start-page: 1413 year: 2020 ident: 1242_CR155 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30453-8 – volume: 27 start-page: 5510 year: 2021 ident: 1242_CR171 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-21-0810 – volume: 15 start-page: e1007468 year: 2019 ident: 1242_CR267 publication-title: PLoS Pathog doi: 10.1371/journal.ppat.1007468 – volume: 128 start-page: 154984 year: 2020 ident: 1242_CR234 publication-title: Cytokine doi: 10.1016/j.cyto.2019.154984 – volume: 112 start-page: E6506 year: 2015 ident: 1242_CR270 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1519623112 – volume: 216 start-page: 982 year: 2019 ident: 1242_CR280 publication-title: J Exp Med doi: 10.1084/jem.20180870 – volume: 173 start-page: 945 year: 2004 ident: 1242_CR116 publication-title: J Immunol doi: 10.4049/jimmunol.173.2.945 – volume: 120 start-page: 317 year: 2019 ident: 1242_CR209 publication-title: Br J Cancer doi: 10.1038/s41416-018-0352-y – volume: 1871 start-page: 199 year: 2019 ident: 1242_CR15 publication-title: Biochim Biophys Acta Rev Cancer doi: 10.1016/j.bbcan.2018.12.002 – volume: 138 start-page: 271 year: 2009 ident: 1242_CR188 publication-title: Cell doi: 10.1016/j.cell.2009.05.046 – volume: 17 start-page: 421 year: 2019 ident: 1242_CR281 publication-title: Mar Drugs doi: 10.3390/md17070421 – volume: 439 start-page: 682 year: 2006 ident: 1242_CR67 publication-title: Nature doi: 10.1038/nature04444 – volume: 10 start-page: 26 year: 2020 ident: 1242_CR183 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-19-0761 – volume: 8 start-page: 1602 year: 2019 ident: 1242_CR208 publication-title: Cells doi: 10.3390/cells8121602 – volume: 38 start-page: 253 year: 2019 ident: 1242_CR266 publication-title: J Exp Clin Cancer Research CR doi: 10.1186/s13046-019-1257-1 – volume: 18 start-page: 10 year: 2019 ident: 1242_CR31 publication-title: Mol Cancer doi: 10.1186/s12943-018-0928-4 – volume: 206 start-page: 3015 year: 2009 ident: 1242_CR68 publication-title: J Exp Med doi: 10.1084/jem.20090847 – volume: 27 start-page: 2212 year: 2021 ident: 1242_CR231 publication-title: Nat Med doi: 10.1038/s41591-021-01544-x – volume: 14 start-page: 793 year: 2019 ident: 1242_CR311 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2019.01.016 – volume: 1 start-page: 533 year: 2020 ident: 1242_CR279 publication-title: Nat Cancer doi: 10.1038/s43018-020-0056-0 – volume: 103 start-page: 11695 year: 2006 ident: 1242_CR108 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0601347103 – volume: 7 start-page: 1420 year: 2017 ident: 1242_CR125 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-17-0593 – volume: 16 start-page: e0251731 year: 2021 ident: 1242_CR255 publication-title: PLoS ONE doi: 10.1371/journal.pone.0251731 – volume: 81 start-page: 158 year: 2021 ident: 1242_CR263 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-20-1674 – volume: 5 start-page: 43 year: 2015 ident: 1242_CR122 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-14-0863 – volume: 46 start-page: 105 year: 2019 ident: 1242_CR100 publication-title: Clin Exp Pharmacol Physiol doi: 10.1111/1440-1681.13056 – volume: 13 start-page: 1725 year: 2021 ident: 1242_CR63 publication-title: Cancers (Basel) doi: 10.3390/cancers13071725 – volume: 197 start-page: 1721 year: 2003 ident: 1242_CR109 publication-title: J Exp Med doi: 10.1084/jem.20022089 – volume: 22 start-page: 1777 year: 2021 ident: 1242_CR232 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(21)00546-5 – volume: 600 start-page: 727 year: 2021 ident: 1242_CR157 publication-title: Nature doi: 10.1038/s41586-021-04161-3 – volume: 81 start-page: 4778 year: 2021 ident: 1242_CR242 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-21-0468 – volume: 7 start-page: 550 year: 2016 ident: 1242_CR111 publication-title: Front Immunol doi: 10.3389/fimmu.2016.00550 – ident: 1242_CR138 – volume: 12 start-page: 2735 year: 2021 ident: 1242_CR1 publication-title: J Cancer doi: 10.7150/jca.57334 – volume: 186 start-page: 2772 year: 2011 ident: 1242_CR79 publication-title: J Immunol doi: 10.4049/jimmunol.1003208 – volume: 41 start-page: 914 year: 2015 ident: 1242_CR117 publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2015.09.006 – volume: 34 start-page: 108620 year: 2021 ident: 1242_CR7 publication-title: Cell Rep doi: 10.1016/j.celrep.2020.108620 – volume: 14 start-page: 149 year: 2015 ident: 1242_CR180 publication-title: Mol Cancer doi: 10.1186/s12943-015-0421-2 – volume: 131 start-page: 141614 year: 2021 ident: 1242_CR238 publication-title: J Clin Investig doi: 10.1172/JCI141614 – volume: 270 start-page: 985 year: 1995 ident: 1242_CR304 publication-title: Science (New York, NY) doi: 10.1126/science.270.5238.985 – volume: 24 start-page: 724 year: 2018 ident: 1242_CR222 publication-title: Nat Med doi: 10.1038/s41591-018-0040-8 – volume: 372 start-page: eaba1786 year: 2021 ident: 1242_CR81 publication-title: Science doi: 10.1126/science.aba1786 – volume: 2 start-page: 919 year: 2021 ident: 1242_CR165 publication-title: Nature Cancer doi: 10.1038/s43018-021-00245-1 – volume: 22 start-page: 1692 year: 2021 ident: 1242_CR140 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(21)00545-3 – volume: 378 start-page: 158 year: 2018 ident: 1242_CR315 publication-title: N Engl J Med doi: 10.1056/NEJMra1703481 – volume: 45 start-page: 7 year: 2016 ident: 1242_CR308 publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2016.02.003 – volume: 36 start-page: 587 year: 2015 ident: 1242_CR112 publication-title: Trends Pharmacol Sci doi: 10.1016/j.tips.2015.06.005 – volume: 386 start-page: 449 year: 2022 ident: 1242_CR139 publication-title: N Engl J Med doi: 10.1056/NEJMoa2111380 – volume: 375 start-page: 2255 year: 2016 ident: 1242_CR221 publication-title: N Engl J Med doi: 10.1056/NEJMoa1609279 – volume: 111 start-page: 3174 year: 2020 ident: 1242_CR274 publication-title: Cancer Sci doi: 10.1111/cas.14529 – volume: 57 start-page: 131 year: 2015 ident: 1242_CR104 publication-title: J Mol Graph Model doi: 10.1016/j.jmgm.2015.01.015 – volume: 149 start-page: 22 year: 2012 ident: 1242_CR187 publication-title: Cell doi: 10.1016/j.cell.2012.03.003 – volume: 59 start-page: 23313 year: 2020 ident: 1242_CR244 publication-title: Angew Chem Int Ed Engl doi: 10.1002/anie.202011273 – volume: 14 start-page: 642 year: 2015 ident: 1242_CR227 publication-title: Nat Rev Drug Discov doi: 10.1038/nrd4663 – volume: 560 start-page: 382 year: 2018 ident: 1242_CR51 publication-title: Nature doi: 10.1038/s41586-018-0392-8 – volume: 8 start-page: 761 year: 2017 ident: 1242_CR61 publication-title: J Cancer doi: 10.7150/jca.17648 – volume: 9 start-page: 32 year: 2018 ident: 1242_CR49 publication-title: Nat Commun doi: 10.1038/s41467-017-02424-0 – volume: 49 start-page: 1360 year: 2016 ident: 1242_CR87 publication-title: Int J Oncol doi: 10.3892/ijo.2016.3632 – volume: 583 start-page: 620 year: 2020 ident: 1242_CR215 publication-title: Nature doi: 10.1038/s41586-020-2502-7 – volume: 292 start-page: 20683 year: 2017 ident: 1242_CR86 publication-title: J Biol Chem doi: 10.1074/jbc.M117.809053 – volume: 9 start-page: 654 year: 2007 ident: 1242_CR98 publication-title: Nat Cell Biol doi: 10.1038/ncb1596 – volume: 27 start-page: 1410 year: 2021 ident: 1242_CR223 publication-title: Nat Med doi: 10.1038/s41591-021-01462-y – volume: 33 start-page: 187 year: 2018 ident: 1242_CR243 publication-title: Cancer Cell doi: 10.1016/j.ccell.2018.01.009 – volume: 48 start-page: 417 year: 2018 ident: 1242_CR9 publication-title: Immunity doi: 10.1016/j.immuni.2018.03.007 – volume: 213 start-page: 561 year: 2015 ident: 1242_CR248 publication-title: Acta Physiol (Oxf) doi: 10.1111/apha.12430 – volume: 12 start-page: 1085 year: 2017 ident: 1242_CR163 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2017.04.014 – volume: 192 start-page: 7 year: 2003 ident: 1242_CR114 publication-title: Immunol Rev doi: 10.1034/j.1600-065X.2003.00008.x – volume: 3 start-page: 1355 year: 2013 ident: 1242_CR96 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-13-0310 – volume: 170 start-page: 3637 year: 2003 ident: 1242_CR64 publication-title: J Immunol doi: 10.4049/jimmunol.170.7.3637 – volume: 11 start-page: 641980 year: 2021 ident: 1242_CR257 publication-title: Front Oncol doi: 10.3389/fonc.2021.641980 – volume: 8 start-page: 57 year: 2020 ident: 1242_CR302 publication-title: Biomarker Res doi: 10.1186/s40364-020-00237-w – volume: 207 start-page: 2187 year: 2010 ident: 1242_CR38 publication-title: J Exp Med doi: 10.1084/jem.20100643 – volume: 9 start-page: 646 year: 2019 ident: 1242_CR186 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-18-1020 – volume: 352 start-page: 227 year: 2016 ident: 1242_CR94 publication-title: Science (New York, NY) doi: 10.1126/science.aac9935 – volume: 6 start-page: 149 year: 2018 ident: 1242_CR296 publication-title: J Immunother Cancer doi: 10.1186/s40425-018-0454-3 – volume: 5 start-page: 1411 year: 2021 ident: 1242_CR230 publication-title: Nat Biomed Eng doi: 10.1038/s41551-021-00826-6 – volume: 67 start-page: 271 year: 2018 ident: 1242_CR204 publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-017-2086-8 – volume: 16 start-page: 102 year: 2018 ident: 1242_CR80 publication-title: J Nanobiotechnol doi: 10.1186/s12951-018-0428-0 – volume: 567 start-page: 479 year: 2019 ident: 1242_CR127 publication-title: Nature doi: 10.1038/s41586-019-1032-7 – volume: 379 start-page: 2108 year: 2018 ident: 1242_CR149 publication-title: N Engl J Med doi: 10.1056/NEJMoa1809615 – volume: 26 start-page: 639 year: 2016 ident: 1242_CR190 publication-title: Cell Res doi: 10.1038/cr.2016.50 – volume: 10 start-page: 5589 year: 2021 ident: 1242_CR262 publication-title: Cancer Med doi: 10.1002/cam4.4114 – volume: 24 start-page: 2071 year: 2019 ident: 1242_CR24 publication-title: Molecules doi: 10.3390/molecules24112071 – volume: 37 start-page: 443 year: 2020 ident: 1242_CR124 publication-title: Cancer Cell doi: 10.1016/j.ccell.2020.03.017 – volume: 12 start-page: 492 year: 2011 ident: 1242_CR50 publication-title: Nat Immunol doi: 10.1038/ni.2035 – volume: 236 start-page: 219 year: 2010 ident: 1242_CR25 publication-title: Immunol Rev doi: 10.1111/j.1600-065X.2010.00923.x – volume: 202 start-page: 3065 year: 2019 ident: 1242_CR191 publication-title: J Immunol doi: 10.4049/jimmunol.1801199 – volume: 15 start-page: 1657 year: 2020 ident: 1242_CR153 publication-title: J Thorac Oncol doi: 10.1016/j.jtho.2020.06.015 – volume: 69 start-page: 1694 year: 2009 ident: 1242_CR46 publication-title: Prostate doi: 10.1002/pros.21020 – volume: 184 start-page: 7 year: 2017 ident: 1242_CR85 publication-title: Immunol Lett doi: 10.1016/j.imlet.2017.02.006 – volume: 5 start-page: 480 year: 2017 ident: 1242_CR52 publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-16-0329 – volume: 5 start-page: 767 year: 2017 ident: 1242_CR273 publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-16-0365 – volume: 21 start-page: 821 year: 2016 ident: 1242_CR135 publication-title: Respirology doi: 10.1111/resp.12789 – volume: 76 start-page: 227 year: 2016 ident: 1242_CR175 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-14-3362 – volume: 34 start-page: 2679 year: 2016 ident: 1242_CR233 publication-title: Vaccine doi: 10.1016/j.vaccine.2016.04.032 – volume: 11 start-page: e0166626 year: 2016 ident: 1242_CR193 publication-title: PLoS ONE doi: 10.1371/journal.pone.0166626 – volume: 40 start-page: 5002 year: 2021 ident: 1242_CR268 publication-title: Oncogene doi: 10.1038/s41388-021-01897-0 – volume: 26 start-page: 677 year: 2008 ident: 1242_CR29 publication-title: Annu Rev Immunol doi: 10.1146/annurev.immunol.26.021607.090331 – volume: 12 start-page: 4445 year: 2021 ident: 1242_CR250 publication-title: Nat Commun doi: 10.1038/s41467-021-24767-5 – volume: 25 start-page: 1163 year: 2017 ident: 1242_CR22 publication-title: Structure doi: 10.1016/j.str.2017.06.011 – volume: 28 start-page: 690 year: 2015 ident: 1242_CR146 publication-title: Cancer Cell doi: 10.1016/j.ccell.2015.10.012 – volume: 16 start-page: 563 year: 2019 ident: 1242_CR316 publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-019-0218-0 – volume: 13 start-page: 10039 year: 2020 ident: 1242_CR201 publication-title: Onco Targets Ther doi: 10.2147/OTT.S247050 – volume: 4 start-page: e1058597 year: 2015 ident: 1242_CR123 publication-title: Oncoimmunology doi: 10.1080/2162402X.2015.1058597 – ident: 1242_CR277 doi: 10.1172/jci.insight.120626 – volume: 11 start-page: 487 year: 2020 ident: 1242_CR36 publication-title: Front Immunol doi: 10.3389/fimmu.2020.00487 – volume: 1779 start-page: 811 year: 2008 ident: 1242_CR78 publication-title: Biochim Biophys Acta doi: 10.1016/j.bbagrm.2008.08.003 – volume: 10 start-page: 2191 year: 2021 ident: 1242_CR2 publication-title: J Clin Med doi: 10.3390/jcm10102191 – volume: 17 start-page: 120 year: 2018 ident: 1242_CR62 publication-title: Mol Cancer doi: 10.1186/s12943-018-0869-y – volume: 33 start-page: 1543 year: 2015 ident: 1242_CR220 publication-title: J Clin Oncol doi: 10.1200/JCO.2014.58.9093 – volume: 12 start-page: 2575 year: 2012 ident: 1242_CR37 publication-title: Am J Transplant doi: 10.1111/j.1600-6143.2012.04224.x – volume: 387 start-page: 1837 year: 2016 ident: 1242_CR310 publication-title: Lancet doi: 10.1016/S0140-6736(16)00587-0 – volume: 9 start-page: 1832760 year: 2020 ident: 1242_CR164 publication-title: Oncoimmunology doi: 10.1080/2162402X.2020.1832760 – volume: 12 start-page: 269 year: 2018 ident: 1242_CR89 publication-title: Mol Oncol doi: 10.1002/1878-0261.12135 – volume: 318 start-page: 1647 year: 2017 ident: 1242_CR57 publication-title: JAMA doi: 10.1001/jama.2017.14155 – volume: 188 start-page: 455 year: 2017 ident: 1242_CR77 publication-title: Clin Exp Immunol doi: 10.1111/cei.12949 – volume: 13 start-page: 6158 year: 2021 ident: 1242_CR258 publication-title: Cancers (Basel) doi: 10.3390/cancers13246158 |
| SSID | ssj0061920 |
| Score | 2.6624894 |
| SecondaryResourceType | review_article |
| Snippet | Immune checkpoint molecules are promising anticancer targets, among which therapeutic antibodies targeting the PD-1/PD-L1 pathway have been widely applied to... Abstract Immune checkpoint molecules are promising anticancer targets, among which therapeutic antibodies targeting the PD-1/PD-L1 pathway have been widely... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 24 |
| SubjectTerms | Animals B cells B7-H1 Antigen - antagonists & inhibitors B7-H1 Antigen - immunology Cancer Chemotherapy Combination therapy Drug resistance Drug therapy Health aspects Humans Immune Checkpoint Inhibitors - pharmacology Immunotherapy Immunotherapy - methods Neoplasms - drug therapy Neoplasms - immunology PD-1/PD-L1 PD-L1 regulation Programmed Cell Death 1 Receptor - antagonists & inhibitors Programmed Cell Death 1 Receptor - immunology Review T cells Tumor Microenvironment |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LaxRBEG4kh-BFfDsaYwuCB2l2-jHT08ckGoKoeDCQW9NPjMqsbDZC_r1V3bPLDoJevCzsVs2wXa-ub6aqmpBX0mQhVTYsZAkARSjHnM4tU9EPGb56kUuV76f-7Fy9v-gudo76wpqwOh64Cm6hhsTz4HJG5BIMd15BkoMjSrTRrSmpEex5GzBVYzCignbTIjP0iyuOLwQZVq5DQMaGlNk2VKb1_xmTdzalecHkzg50epfcmVJHelT_8j1yK433yf7H6eX4A_KtPiAoz_voMlNI7SjIDeNcSCuacFiECzdI-vyW8QV8fODUw2723cVEf106CuYHSLkoi9bOrBu4RaSVdVXPrQfiQ3J--u7LyRmbjlJgoZdizWSGzCDITvrWcQE5mpM8i5i1AJEarxUAG-mzg2QmaCcGrl2bIIaa2OsoRZSPyN64HNMTQrnvdXC5H3AKqTHBxEHEvs06CtOlVjWEbyRrwzRnHI-7-GEL3hh6W7VhQRu2aMOKhrzZXvOzTtn4K_cxKmzLiROyyw9gN3ayG_svu2nIC1S3re2mWz-3R70xHYA8xRvyunCgp8MCQEO1YQHEgDOzZpwHM07w0DAjv9yYlEUSlrWNaXl9ZQXmi8CiuoY8ria2XRVkxtoAYGyInhnfbNlzynj5tQwIHwCDQyR_-j_k9IzcFsVvJOPigOytV9fpOeRha39YXO43FcEp1g priority: 102 providerName: Directory of Open Access Journals |
| Title | Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35279217 https://www.proquest.com/docview/2638960445 https://pubmed.ncbi.nlm.nih.gov/PMC8917703 https://doaj.org/article/48e1f8aff6144c91ab4080684079709a |
| Volume | 15 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3db9MwED_tQ0K8IL4JjGIkJB5QWPyROH5AqINNU8WmCajUN8txYhhMLaQdov89ZzuNFjEhXlq1vqay7_Nn--4AXnDlGBdOpdZxBChMmNRIl6WirkqHHyvmwi3f0-J4KiazfLYFm3ZH3QIur4V2vp_UtL14_fvn-i0q_Jug8GWxv6T-uC_199LR3Pp0k23YRc8kvaKeiP5UwWOFmCCZF2gFGNsk0Vz7jIGjCvX8_7baV9zW8ErlFR91dBtudcElGUdpuANbzfwu3Djpjs_vwbe4hRB2BMnCEQz-CK6st4S2aUnjy0kYu_ZDZ-9Tuo8vHyip0N99N3VDfp0bggKKWDqwk8TcrTU-oiaRtI2d7XHwPkyPDj-_O067ZgupLThbpdxh7GB5zqvMUIZRnOHUsdpJZhVVlRQIfXjlDIY7VhpWUmmyBq2sqgtZc1bzB7AzX8ybR0BoVUhrXFH6OqVKWVWXrC4yJ2um8iYTCdDNymrbVSL3DTEudEAkZaEjNzRyQwduaJbAq_43P2Idjn9SH3iG9ZS-hnb4YtF-0Z1KalE21JXGOY-JcZKmEhg---I3UslMmQSeeXbrmJDaWwI9LpTKEQYKmsDLQOGlEyeAHIopDbgMvqrWgHJvQIk6bAfDzzcipf2Qv_g2bxaXS818RIkkIk_gYRSxflYYO0uFkDIBORC-wbSHI_Pzr6GEeIkoHW394__43ydwkwW14Clle7Czai-bpxiIraoRbMuZHMHueDz5NMH3g8PTs4-jsK0xCpr3B8EWLlk |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Improvement+of+the+anticancer+efficacy+of+PD-1%2FPD-L1+blockade+via+combination+therapy+and+PD-L1+regulation&rft.jtitle=Journal+of+hematology+and+oncology&rft.au=Wu%2C+Mengling&rft.au=Huang%2C+Qianrui&rft.au=Xie%2C+Yao&rft.au=Wu%2C+Xuyi&rft.date=2022-03-12&rft.issn=1756-8722&rft.eissn=1756-8722&rft.volume=15&rft.issue=1&rft.spage=24&rft_id=info:doi/10.1186%2Fs13045-022-01242-2&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-8722&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-8722&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-8722&client=summon |